Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Gilbert PB, Montefiori DC, McDermott A, et al. Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial

Table of Contents

Immune Assays Team
Moderna, Inc. Team
Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE) Team7
CoVPN/COVE Team (cont'd): COVE Trial Investigators and Study Teams10
United States Government (USG)/Coronavirus Prevention Network (CoVPN) Biostatistics Team. 20
Figure S1. Timing of mRNA-1273 doses, blood sampling, and the two time periods for diagnosis of COVID-19 endpoints ("Intercurrent" and "Post Day 57")
Figure S2. Flowchart of study participants from enrollment to the case-cohort set of baseline SARS- CoV-2 negative per-protocol participants
Supplementary Text 1: Additional details on the immunoassays
Solid-phase electrochemiluminescence S-binding IgG immunoassay (ECLIA)23
Neutralization assay23
Calibrated neutralization titers (cID50 and cID80)24
Table S1. Meso-Discovery (MSD) and pseudovirus neutralization assay limits of the four antibodymarkers evaluated as immune correlates.26
Supplementary Text 2: Baseline covariates adjusted for in immune correlates analyses, including the baseline COVID-19 risk score
Table S2. Individual baseline variables input into the Superlearner model for predictingoccurrence of COVID-19 in baseline SARS-CoV-2 negative per-protocol placeborecipients.1
Table S3. Learning algorithm-screen combinations (14 in total) used as input to the Superlearner model in baseline negative per-protocol placebo recipients. 29
Table S4. Weights assigned by Superlearner to each individual learner in the modeling of the placebo arm 30
Table S5. Predictors in learners assigned positive weight by Superlearner in the modeling of the placebo arm
Figure S3. (A) Cross-validated receiver operating characteristic curve for the 2 top- performing learners, Superlearner, and the Discrete Superlearner models classifying COVID-19 outcome occurrence in baseline SARS-CoV-2 negative per-protocol placebo recipients, with cross-validated area under the curve (CV-AUC) summarizing classification performance. (B) Receiver operating characteristic curve for the Superlearner upon applying the model built from placebo recipients to baseline SARS-CoV-2 negative per- protocol vaccine recipients, with AUC in parentheses summarizing classification performance
Figure S4. Superlearner model predicted probabilities of the COVID-19 endpoint starting 7 days post Day 57 visit by case vs. non-case (i.e., control) status, for baseline SARS-CoV-2 negative per-protocol vaccine recipients in the case-cohort set

Table S6. Numbers of participants in the case-cohort set by baseline sampling strata
Table S7. Demographics and clinical characteristics of baseline SARS-CoV-2 negative per-protocoltrial participants in the immunogenicity subcohort and thus have Day 1, 29, 57 antibody markerdata
Figure S5. For each antibody marker, correlations of Day 29 levels with Day 57 levels in baseline SARS-CoV-2 negative per-protocol vaccine recipients in the immunogenicity subcohort. Corr = baseline variable adjusted Spearman rank correlation
Figure S6. Correlations of Day 29 antibody markers in baseline SARS-CoV-2 negative per-protocol vaccine recipients in the immunogenicity subcohort
Figure S7. Correlations of Day 57 antibody markers in baseline SARS-CoV-2 negative per-protocol vaccine recipients in the immunogenicity subcohort
Figure S8. A) Anti-RBD IgG concentration and B) pseudovirus neutralization cID80 titer by COVID-19 outcome status
Figure S9. Marker values (Spike IgG, RBD IgG, cID50, cID80) by COVID-19 outcome status in placebo recipients
Figure S10. Day 29 marker data points from baseline SARS-CoV-2 negative per-protocol vaccine recipients selected into the case-cohort set
Figure S11. Day 57 marker data points from baseline SARS-CoV-2 negative per-protocol vaccine recipients selected into the case-cohort set
Figure S12. Inverse probability sampling (IPS)-weighted empirical reverse cumulative distribution function curves for each Day 57 marker (Spike IgG, RBD IgG, cID50, cID80) and application of the Siber (2007) method ¹¹ for estimating a threshold of perfect vs. no protection. cID50, cID80: calibrated ID50, ID80 titer
Figure S13. Inverse probability sampling (IPS)-weighted empirical reverse cumulative distribution function curves for each Day 29 marker (Spike IgG, RBD IgG, cID50, cID80) and application of the Siber (2007) method ¹¹ for estimating a threshold of perfect vs. no protection. cID50, cID80: calibrated ID50, ID80 titer
Figure S14. Day 29 and Day 57 antibody markers (Spike IgG, RBD IgG, cID50, cID80) vs. number of days from Day 29 visit until COVID-19 primary endpoint diagnosis for per-protocol baseline SARS-CoV-2 negative vaccine recipient breakthrough cases
Figure S15: Covariate-adjusted cumulative incidence of COVID-19 by Low, Medium, High tertile of Day 57 IgG concentration or pseudovirus neutralization titer. (A) Anti-RBD IgG concentration; (B) cID80 titer
Figure S16. Covariate-adjusted cumulative incidence of COVID-19 by Low, Medium, High tertile of Day 29 IgG concentration or pseudovirus neutralization titer
Figure S17: Covariate-adjusted cumulative incidence of COVID-19 by Low, Medium, High tertile of Day 29 IgG concentration or pseudovirus neutralization titer. (A) Anti-RBD IgG concentration; (B) cID80 titer
Figure S18. Covariate-adjusted hazard ratios of COVID-19 per 10-fold increase in each Day 29 antibody marker in baseline SARS-CoV-2 negative per-protocol vaccine recipients overall and in subgroups

Figure S19. Covariate-adjusted risk of COVID-19 by the level of each Day 57 marker (Spike IgG, RBD IgG, cID50, cID80), estimated with a generalized additive model
Figure S20. Covariate-adjusted risk of COVID-19 by the level of each Day 29 marker (Spike IgG, RBD IgG, cID50, cID80), estimated with a generalized additive model
Figure S21. (A) Covariate-adjusted risk of COVID-19 by subgroups defined by Day 57 cID80 level above a threshold, with reverse cumulative distribution function of Day 57 cID80 level overlaid in green; (B) Covariate-adjusted cumulative incidence of COVID-19 by 100 days post Day 57 by Day 57 cID80 level; (C) Vaccine efficacy by Day 57 cID80 level
Figure S22. (A) Covariate-adjusted risk of COVID-19 by subgroups defined by Day 57 Anti-Spike IgG level above a threshold, with reverse cumulative distribution function of Day 57 Anti-Spike IgG level overlaid in green; (B) Covariate-adjusted cumulative incidence of COVID-19 by 100 days post Day 57 by Day 57 Anti-Spike IgG level; (C) Controlled vaccine efficacy by Day 57 Anti-Spike IgG level
Figure S23. (A) Covariate-adjusted risk of COVID-19 by subgroups defined by Day 57 Anti-RBD IgG level above a threshold, with reverse cumulative distribution function of Day 57 Anti-RBD IgG level overlaid in green; (B) Covariate-adjusted cumulative incidence of COVID-19 by 100 days post Day 57 by Day 57 Anti-RBD IgG level; (C) Controlled vaccine efficacy by Day 57 Anti-RBD IgG level
Figure S24. (A) Covariate-adjusted risk of COVID-19 by subgroups defined by Day 29 cID50 level above a threshold, with reverse cumulative distribution function of Day 29 cID50 level overlaid in green; (B) Covariate-adjusted cumulative incidence of COVID-19 by 126 days post Day 29 by Day 29 cID50 level; (C) Controlled vaccine efficacy by Day 29 cID50 level
Figure S25. (A) Covariate-adjusted risk of COVID-19 by subgroups defined by Day 29 cID80 level above a threshold, with reverse cumulative distribution function of Day 29 cID80 level overlaid in green; (B) Covariate-adjusted cumulative incidence of COVID-19 by 126 days post Day 29 by Day 29 cID80 level; (C) Controlled vaccine efficacy by Day 29 cID80 level
Figure S26. (A) Covariate-adjusted risk of COVID-19 by subgroups defined by Day 29 Anti-Spike IgG level above a threshold, with reverse cumulative distribution function of Day 29 Anti-Spike IgG level overlaid in green; (B) Covariate-adjusted cumulative incidence of COVID-19 by 126 days post Day 29 by Day 29 Anti-Spike IgG level; (C) Controlled vaccine efficacy by Day 29 Anti-Spike IgG level
Figure S27. (A) Covariate-adjusted risk of COVID-19 by subgroups defined by Day 29 Anti-RBD IgG level above a threshold, with reverse cumulative distribution function of Day 29 Anti-RBD IgG level overlaid in green; (B) Covariate-adjusted cumulative incidence of COVID-19 by 126 days post Day 29 by Day 29 Anti-RBD IgG level; (C) Controlled vaccine efficacy by Day 29 Anti-RBD IgG level
Supplementary Text 3: Controlled vaccine efficacy sensitivity analysis to assess robustness of the effect of antibody marker on preventing COVID-19 to unmeasured confounding
Table S8. Sensitivity analysis to assess Day 57 and Day 29 antibody markers categorized as upper vs. lower tertiles as controlled vaccine efficacy CoPs against COVID-19
Figure S28. Vaccine efficacy with sensitivity analysis by Day 57 (A) Anti-Spike IgG level, (B) Anti-RBD IgG level, (C) cID50 level, or (D) cID80 level

Figure S29. Vaccine efficacy with sensitivity analysis by Day 29 (A) Anti-Spike IgG level, (B) Anti-
RBD IgG level, (C) cID50 level, or (D) cID80 level.63
Table S9. Table of mediation effect estimates for quantitative markers with 95% confidence
intervals
References

Affiliation	Team Members
Biomedical Advanced Research and Development Authority (BARDA), Washington, DC	Christophe S. Badorrek, Oleg Borisov, Flora Castellino, Brett Chromy, Mark Delvecchio, Ruben O. Donis, Tremel Faison, Corey Hoffman, Christopher Houchens, Tom Hu, Chuong Huynh, Pennie Hylton, Lakshmi Jayashankar, Aparna Kolkehar, James Little, Karen Martins, Jeanne Novak, Jeane Russell, Gregory E. Rutkowski, Carol Sabourin, Evan Sturtevant, Xiaomi Tong, John Treanor, Danielle Turley, Leah Watson
Boston Consulting Group, Boston, MA	Gian King, Andrew Li, Najaf Shah, Smruthi Suryaprakash, Jue Xiang Wang
Division of AIDS, NIAID, NIH, Bethesda, MD	Patricia D'Souza
Duke University, Durham, NC	David Beaumont, Rebecca Beerman, Kendall Bradley, Jiayu Chen, Xiaoju Daniell, Thomas Denny, Elizabeth Domin, Amanda Eaton, Kelsey Engle, Wenhong Feng, Juanfei Gao, Hongmei Gao, Kelli Greene, Sarah Hiles, Marianne Jessup-Cumming, Marcella Sarzotti- Kelsoe, Kristy Long, Kellen Lund, Kaia Lyons, Charlene McDanal, David C. Montefiori, Francesca Suman, Haili Tang, Jin Tong, Olivia Widman
Vaccine Research Center, NIAID, NIH, Bethesda, MD	Akua Abrah, Obrimpong Amoa-Awua, Manjula Basappa, Robin Carroll, Erykah Coe, Jevone Fentress, Britta Flach, Supra Gajjala, Nazaire Jean-Baptiste, Richard A. Koup, Bob C. Lin, Adrian McDermott, Christopher Moore, Mursal Naisan, Muhammed Naqvi, Sandeep Narpala, Sarah O'Connell, Abhinaya Srikanth, Clare Whittaker, Weiwei Wu

Immune Assays Team. (PubMed listed, and ordered alphabetically by affiliation)

Moderna, Inc. Team. (PubMed listed, ordered alphabetically)

Affiliation	Team Members
Moderna, Inc., Cambridge, MA	Weiping Deng, Shu Hahn, Jacqueline Miller, Rolando Pajon, Honghong Zhou

Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE) Team. (PubMed listed, and ordered alphabetically by institution affiliation)

Affiliation/Funding*	Study Group	Location
AB Clinical Trials	Atoya Adams, MD, MBA, Eric Miller	Las Vegas, NV
Accel Research Sites	Bruce G. Rankin DO, John Hill MD, Steven Shinn MD, Marshall Nash MD	DeLand, FL
Advanced Clinical Research	Sinikka L. Green MD, Colleen Jacobsen, Jayasree Krishnankutty, Sikhongi Phungwayo	Cedar Park, TX
Alliance for Multispecialty Research	Richard M. Glover, II MD, Drs. Stacy Slechta, Troy Holdeman, Robyn Hartvickson, Amber Grant	Newton, KS
Alliance for Multispecialty Research	Terry L. Poling MD, Terry D. Klein MD, Thomas C. Klein MD, Tracy R. Klein MD	Wichita, KS
Alliance for Multispecialty Research	William B. Smith MD, Richard L. Gibson MD, Jennifer Winbigler MD, Elizabeth Parker PA	Knoxville,TN
Baptist Health Center for Clinical Research	Priyantha N. Wijewardane, MD, Eric Bravo MD, Jeffrey Thessing MD, Michelle Maxwell APRN, Amanda Horn APRN	Little Rock, AR
Baylor College of Medicine, NIAID 1UM1AI148575-01S2	Hana El Sahly MD, Jennifer Whitaker MD, Catherine Mary Healy MD, Christine Akamine MD	Houston, TX
Benchmark Research	Laurence Chu, MD, R. Michelle Chouteau, MD	Austin, TX
Benchmark Research	Michael J. Cotugno MD, George H. Bauer, Jr. MD	Metairie, LA
Benchmark Research	Greg Hachigian MD, Masaru Oshita MD, Michael Cancilla NP, Deborah Murray NP, Kristen Kiersey NP	Sacramento, CA
Benchmark Research	William Seger MD, Mohammed Antwi, Allison Green, Anthony Kim	Fort Worth, TX
Brigham and Women's Hospital, NIAID UM1AI069412, NCATS UL1RR025758	Lindsey R Baden MD, Michael Desjardins MD, Jennifer A Johnson MD, Amy Sherman MD, Stephen R Walsh MD	Boston, MA
Carolina Institute for Clinical Research	Judith Borger DO, Ryan Starr DO, Scott Syndergaard DO, Nafisa Saleem MD	Fayetteville, NC
Centex Studies	Joel Solis MD, Martha Carmen Medina PA-C, Westly Keating PA-C, Edgar Garcia PA-C, Cynthia Bueno PA-C	McAllen, TX
Clinical Research Atlanta	Nathan Segall MD, Nathan Segall, Jon Finley, Mildred Stull	Stockbridge, GA
Clinical Trials of Texas	Douglas Scott Denham DO, Thomas Weiss MD, Ayoade Avworo DNP, Parke Hedges MD	San Antonio, TX
Coastal Carolina Research Center	Cynthia Becher Strout MD, Rica Santiago, Yvonne Davis, Patty Howenstine, Alison Bondell	Mount Pleasant, SC
Cornell Clinical Trials Unit - Weill Cornell Uptown & Weill Cornell Chelsea, NIAID UM1Al068619, NCAT UL1TR002384	Kristin Marks MS MD, Grant Ellsworth, MS, MD, Tina Wang, MD, Timothy Wilkin, MD, MPH, Mary Vogler, MD, Carrie Johnston, MD, MS	New York, NY
Covid19 Prevention Network (CoVPN, NIAID-NIH)	Michele P Andrasik, Jessica G Andriesen, Gail Broder, Lawrence Corey, Niles Eaton, Kathleen M Neuzil, Huub G Gelderblom, James G Kublin, Rachael McClennen, Nelson Michael, Merlin Robb, Carrie Sopher	Seattle, WA
DM Clinical Research	Vicki E. Miller MD, MPH, Fredric Santiago MD, Blanca Gomez FNP-C, Insiya Valika PA-C, Amy Starr FNP-C	Tomball, TX
Emory University – Ponce de Leon Clinical Research Site, NIAID 3UM1AI068614-14S1	Colleen Kelley MD MPH, Valeria D Cantos MD, Sheetal Kandiah MD MPH, Carlos del Rio MD	Atlanta, GA
Emory University – Hope Clinic, NIAID 1UM1AI148576-01	Nadine Rouphael MD, Paulina Rebolledo, Srilatha Edupuganti, Daniel Sans Graciaa	Decatur, GA
Emory University School of Medicine, NIAID 1UM1AI148576-01	Evan J Anderson MD, Andres Camacho-Gonzalez MD, Satoshi Kamidani MD, Christiana A Rostad MD, Meghan Teherani MD	Atlanta, GA
George Washington University, NIAID UM1AI068619	David Joseph Diemert MD, Elissa Malkin, Marc Siegel, Afsoon Roberts, Gary Simon	Washington, DC
Hackensack University Medical Center	Bindu Balani MD, Carolene Stephenson, Steven Sperber, Cristina Cicogna	Hackensack, NJ
Henry Ford Health System	Marcus J. Zervos MD, Paul Kilgore MD, MPH, Mayur Ramesh MD, Erica Herc MD, Kate Zenlea MPH	Detroit, MI
Hope Research Institute	Abram Burgher MD, Ann Marie Milliken	Phoenix, AZ
Hope Research Institute	Joseph D. Davis MD, Brendan Levy, Sandra Kelman	Chandler, AZ
Hope Research Institute	Matthew W. Doust MD, Denise Sample, Sandra Erickson	Phoenix, AZ
J. Lewis Research	Shane Glade Christensen MD, Christopher Matich, James Longe, John Witbeck	Salt Lake City, UT
J. Lewis Research	James Todd Peterson MD, Alexander Clark, Gerald Kelty, Issac Pena-Renteria	Salt Lake City, UT
	· · · · · · · · · · · · · · · · · · ·	1

Affiliation/Funding*	Study Group	Location
Javara	Christina Kennelly MD, Robert Brownlee, Jacob Coleman, Hala Webster	Charlotte, NC
Johnson County Clin-Trials	Carlos A. Fierro MD, Natalia Leistner, Amy Thompson, Celia Gonzalez	Lenexa, KS
Kaiser Permanente Washington Health Research Institute, NIAID 1UM1AI148373-01	Lisa A Jackson MD MPH, Janice Suyehira MD	Seattle, WA
Laguna Clinical Research Associates	Milton Haber MD, Maria M. Regalado MD, Veronica Procasky RN JD, Alisha Lutat	Laredo, TX
Lynn Health Science Institute	Carl P. Griffin MD, Raymond Cornelison, William Schnitz, Shanda Gower	Oklahoma City, OK
Lynn Institute of the Rockies	Ripley R. Hollister MD, Jeremy Brown DO, Melody Ronk PA-C	Colorado Springs, CO
M3 Wake Research	Wayne Lee Harper MD, Lisa Cohen DO, Lynn Eckert PA-C, Matthew Hong MD	Raleigh, NC
MediSync Clinical Research Hattiesburg Clinic	Rambod Rouhbakhsh MD, MBA, Elizabeth Danford MD, John Johnson MD, Richard Calderone MD	Petal, MS
Meridian Clinical Research	Shishir Kumar Khetan MD, Oyebisi Olanrewaju AC-CRNP, Nan Zhai NP-C, Kimberly Nieves AC-CRNP, Allison O'Brien AC-CRNP	Rockville, MD
Meridian Clinical Research	Paul Simon Bradley MD, Amanda Lilienthal MSN NP-C, Jim Callis PA-C	Savannah, GA
Meridian Clinical Research	Adam Benson Brosz MD, Andrea Clement PA, Whitney West APRN, Luke Friesen PA, Paul Cramer APRN	Grand Island, NE
Meridian Clinical Research	Frank Steven Eder MD, Ryan Little FNP, Victoria Engler FNP, John Tarbox FNP, Heather Rattenbury-Shaw DO	Binghamton, NY
Meridian Clinical Research	David Jon Ensz MD, Tavane Harrison, Allie Oplinger	Dakota Dunes, SD
Meridian Clinical Research	Brandon James Essink MD, Jay Meyer MD, Frederick Raiser, III MD, Kimberly Mueller APRN, Roni Gray PA	Omaha, NE
Meridian Clinical Research	Keith William Vrbicky MD, Charles Harper MD, Chelsie Nutsch MD, Wendell Lewis III MD, Cathy Laflan MD	Norfolk, NE
Meridian Clinical Research	Jordan L. Whatley MD, Nicole Harrell MD, Amie Shannon MD, Crystal Rowell APRN, FNP- C, Christopher Dedon APRN, FNP-C	Baton Rouge, LA
NIH	Mamodikoe Makhene MD MPH	Bethesda, MD
New Horizons Clinical Research	Gregory Mark Gottschlich MD, Kate Harden PA-C, Melissa Gottschlich PA-C, Mary Smith MSN, FNP-C, Richard Powell MD	Cincinnati, OH
Optimal Research	Murray A. Kimmel DO, Simmy Pinto MD	Melbourne, FL
Optimal Research	Timothy P. Vachris MD, Mark Hutchens MD, Stephen Daniels DO, Margaret Wells MD	Austin, TX
Optimal Research	Mimi Van Der Leden MD, PhD, Peta Gay Jackson Booth MD	Rockville, MD
Palm Beach Research Center	Mira Baron MD, Pamela Kane DO, Shannen Seversen PA-C, Mara Kryvicky PA-C, Julia Lord PA-C	West Palm Beach, FL
Paradigm Clinical Research Center	Jamshid Saleh MD, Matthew Miles, Rafael Lupercio	Redding, CA
Quality of Life Medical & Research Centers	John W. McGettigan Jr. MD, Walter Patton MD, Riemke Brakema MD, Karin Choquette MSN, ABNP-C, Jonlyn McGettigan MSN, RN	Tucson, AZ
Rancho Paseo Medical Group	Judith L. Kirstein MD, Marcia Bernard NP	Banning, CA
Rapid Medical Research	Mary Beth Manning MD, Joan Rothenberg MD, Toby Briskin MD, Denise Roadman PAC, Sharita Tedder-Edwards FNP	Cleveland, OH
Research Centers of America	Howard I. Schwartz MD, Surisday Mederos, Barbara Corral, Jennifer Schwartz, Nelia Sanchez-Crespo	Hollywood, FL
Rutgers New Jersey Medical School, NIAID UM1Al068619	Shobha Swaminathan MD, Amesika Nyaku MD MS, Tilly Varughese MD, Michelle DallaPiazza MD	Newark, NJ
Saint Louis University, NIAID 1UM1AI148685-01	Sharon E Frey MD, Irene Graham MD, Getahun Abate MD PhD MSc, Daniel Hoft MD PhD	St. Louis, MO
St. Vincent's Health System	Leland N. Allen III MD, Leslie Anne Edwards MSN, CRNP, William Simpson Davis Jr., MS PA-C, Jessica Maria Mena, PA	Birmingham, AL
Suncoast Research Group	Mark E. Kutner MD, Jorge Caso MD, CPI, Maria Hernandez Moran APRN, Marianela Carvajal APRN, Janet Mendez APRN	Miami, FL
Sundance Clinical Research	Larkin T. Wadsworth III MD, Horacio Marafioti, Lyly Dang, Jennifer Berry, Lauren Clement	St. Louis, MO
Synexus Clinical Research	Michael Ryan Adams MD, Leslie Iverson PA	Murray, UT
Synexus Clinical Research	Joseph Lee Newberg MD, Laura Pearlman MS, MD, MBA	Chicago, IL
Synexus Clinical Research	Paul Joseph Nugent DO, Leonard Singer	Cincinnati, OH
Synexus Clinical Research	Michele Diane Reynolds MD, Jennifer Bashour MD, Robert Schmidt MD	Dallas, TX
Synexus Clinical Research	Neil Parmanand Sheth MD, Kenneth Steil DO	Glendale, AZ

Affiliation/Funding*	Study Group	Location
Synexus Clinical Research	Ramy Joseph Toma MD, William Kirby MD, Pink Folmar MD, Samantha Williams NP	Birmingham, AL
Synexus Clinical Research	s Clinical Research Judith White MD, Robert Meyer MD, Sejal Patel MD, Prity Patel APRN	
Tekton Research	Paul Pickrell MD, Stefanie Mott FNP-C, Carol Ann Linebarger MD, Hussain Malbari MD, David Pampe MD	Austin, TX
Texas Center for Drug Development	Veronica G. Fragoso MD, Lisa Holloway MD, Cecilia McKeown-Bragas MD, Teresa Becker MD, Vicki Miller MD	Houston, TX
Trial Management Associates	Barton G. Williams MD, William H. Jones MD	Wilmington, NC
VA Greater Los Angeles Healthcare System	Michael Lewis MD, Elham Ghadishah, Joseph Yusin, Mai Pham	Los Angeles, CA
University of California Los Angeles, NIAID UM1AI068619	Jesse L Clark MD, Steven Shoptaw PhD, Michele Vertucci PA, NP, Will Hernandez NP	Los Angeles, CA
University of California San Diego, NIAID UM1Al068636	Stephen A. Spector MD, Amaran Moodley MD, Jill Blumenthal MD, Lisa Stangl NP, Karen Deutsch NP	La Jolla, CA
University of Chicago	Kathleen M. Mullane DO PharmD, David Pitrak MD, Cheryl Nuss FNP, Judy Pi PharmD	Chicago, IL
University of Cincinnati, NIAID UN1AI068619	Carl Fichtenbaum MD, Margaret Powers-Fletcher PhD, Michelle Saemann RN, Sharon Kohrs RN	Cincinnati, OH
University of Colorado Denver, Anschutz Medical Campus, NIAID UM1AI068636	Thomas B. Campbell MD, Andrew Lauria, Jose Castillo Mancilla, Hillary Dunlevy	Aurora, CO
University of Illinois at Chicago – Project WISH, NIAID UM1Al068619	Richard M Novak MD, Andrea Wendrow, Scott Borgetti, Ben Ladner	Chicago, IL
University of Maryland School of Medicine, NIAID 1UM1AI148689-01	Karen L Kotloff MD, Matthew Laurens, Milagritos Tapia, Lisa Chrisley, Cheryl Young	Baltimore, MD
University of Miami, NIAID 3UM1AI068614-14S1	Susanne Doblecki-Lewis MD, Maria Luisa Alcaide, Jose Gonzales-Zamora, Stephen Morris	Miami, FL
University of North Carolina at Chapel Hill, NIAID UM1Al068619	Cynthia Gay MD MPH, David Wohl MD, Joseph Eron, Jr. MD	Chapel Hill, NC
University of Pennsylvania, NIAID 3UM1AI068614-14S1	Ian Frank MD, Debora Dunbar, David Metzger, Florence Momplaisir	Philadelphia, PA
University of Pittsburgh Medical Center, NIAID 1UM1AI148452-01	Judith Martin MD, Alejandro Hoberman MD, Timothy Shope MD MPH, Gysella Muniz MD	Pittsburgh, PA
University of Texas Medical Branch, NIAID 1UM1AI148575-01	Richard Rupp MD, Amber Stanford PA-C, Megan Berman MD, Laura Porterfield MD	Galveston, TX
VA Greater Los Angeles Healthcare System	Michael Lewis MD, Elham Ghadishah, Joseph Yusin, Mai Pham	Los Angeles, CA
Vanderbilt University Medical Center, NIAID 1UM1AI148452-01	Clarence Buddy Creech II MD, Shannon Walker MD, Stephanie Rolsma MD PhD, Robert Samuels, Isaac Thomsen MD	Nashville, TN
Vanderbilt University Medical Center, NIAID 3UM1AI068614-14S1	Spyros Andrews Kalams MD, Greg Wilson MD	Nashville, TN
Velocity Clinical Research	Gregg H. Lucksinger MD, Kevin Parks MD, Ryan Israelsen MD, Jaleh Ostovar FNP-C, Kary Kelly FNP-C	Medford, OR
Velocity Clinical Research, San Diego	Jeffrey Scott Overcash MD, Hanh Chu, Kia Lee, Karla Zepeda	La Mesa, CA
VitaLink Research	Luis I. De La Cruz MD, Steve Clemons, Elizabeth Everette, Suzanna Studdard	Greenville, SC
VitaLink Research	Gowdhami Mohan MD, Stefanie Tyson, Alyssa-Kay Peay, Danyel Johnson	Anderson, SC
VitaLink Research-Spartanburg	Gregory J. Feldman MD, May-Yin Suen, Jacqueline Muenzner, Joseph Boscia, Farhan Siddiqui	Spartanburg, SC
Wake Forest University Health Sciences	John Sanders MD,PhD, James Peacock MD, Julio Nasim MD	Winston Salem, NC
WR-Clinical Research Center of Nevada	Michael L. Levin MD, Julie Hussey MSN APRN FNP-C, Marcy Kulic MD	Las Vegas, NV
WR-ClinSearch	Mark Montgomery McKenzie MD, Teresa Deese, Erica Osmundsen, Christy Sweet	Chattanooga, TN
WR-Global Medical Research	Valentine Mbepson Ebuh MD MA MSc, Elwaleed Elnagar MD, Georgette Ebuh DNP APRN FNP-C, Genevieve Iwuala FNP	Dallas, TX
WR-Medical Center for Clinical Research	Laurie J. Han-Conrad MD, Todd Simmons MD, Denis Tarakjian MD	San Diego, CA
	titute of Allergy and Infectious Discoses (AllAID) and/or research support by the National Conta	. (

*Funding of institutions by the National Institute of Allergy and Infectious Diseases (NIAID) and/or research support by the National Center for Advancing Translational Science (NCATS) as indicated. All other institutions were funded by Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority. The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of the funding sources.

Principal Investigator	Study Team	Institution	Location
Atoya Adams, MD, MBA	Miriah Campbell, Eric Miller, Daisy Langarica, Alia Bober, Diana Giraldo	AB Clinical Trials	Las Vegas, NV
Michael Ryan Adams, MD	Leslie Iverson, Andryelle Toledo, Melinda Bullington, Alicia Hanten, Carolyn Taylor, Shannon Wright, Chase Carnahan, Rachel Law, Natalie Smith, Julie Taylor, Jared- Robert Blake, Stefanie Vasconez, Courtney Jensen	Synexus Clinical Research	Murray, UT
Leland N. Allen III, MD	Leslie Anne Edwards, William Simpson Davis, Jr., Ronald Meza, Jordan Stauffer, John Farringer, Faith Holmes, Rhonda Buzbee, Cristina Velez, Huse Lisa, Lisa Huse, Camelia Speegle, Gregory Prestage, Mary Perez, Jessica Space, Matthew Todd, Jessica McDowell, Marha Bunnell-Pollak, Jackie Ziegler, Jasmine Ali, Dumitru Sirbu, Kellie Williams, Logan Sawyer, Richelle Chambliss, Samantha Blackmon, Stephanie Brennan, Tiffany Gibbs, Alexandria Anderson, Caitlin Roll, Candace Robinson, Zachary McCoy, Jessica Bartlett, Kimberly Cornelison, Chris Bovell, Vincent Baglini, Christy Greenhalgh, Jessica Maria Mena, David House, Matt Honold, Esteban Zurita	St. Vincent's Health System	Birmingham, AL
Evan J. Anderson, MD	Kathleen Stephens, Francine Dyer, Maya Stagg, Aaliyah Carron, Austin Lu, Julia Barton, Sy Tran, Leisa Bower, Esther Park, Jianguo Xu, Rebecca Gonzalez, Vy Ngo, Mike Shepard, Lezly Roxxette Zepeda, Karen Sytsma, Sandra Rojas-Honan, Felicia Glover, Susan Rogers, Theda Gibson, Christina A. Rostad, Andres Camacho- Gonzalez, Teresa Ball, Satoshi Kamidani, Mehgan Farah Teherani, Vikash Patel, Etza Peters, Peggy Kettle, Lisa Macoy, Cindy Lubbers, Amber Samuel, Laila Hussaini, Kathryn Zaks, Caroline Ciric, Meg Taylor, Oliver Smith, Amy Muchinsky, Sydney Biccum, Laura Clegg, Dean Kleinhenz, Angelle Ijeoma, Hannah Huston	Emory University School of Medicine	Atlanta, GA
Lindsey Baden, MD	Xhoi Mitre, Jon Gothing, Bruce Bausk, Jessica Cauley, Natalie Izaguirre, Lewis Novack, Michael Seaman, Katherine Yanosick, Henry Rutherford, Junghyun Kim, Dominique Betterbed, Kathleen Garvey, Lauren Clore, Alexander Mills, Deepesh Duwadi, Alessandra Setaro, Kyl Bowman, Kevin McManus, Sidali Beriane, Fadi Ghantous, Christy Lavine, Jasper Ophel, Joseph Sapiente, Jessica Dorning, Tessa Speidel, Lauren Garneau, Robert Dannemiller, Kirquenique Rolle, Mulika Chhom, Bailey McCarthy, Hana Flaxman, Milenko Tanasijevic, Cameron Nutt, Javier Barria, Andre Avila-Paz, Buteau Malhaika, Tong Alexandra, Tenaizus Woods, Bethany Evans, Hannah Jin, LaKeisha Gandy, Stephanie St. Pierre, Carolyn Darcy, Michael Corrado, James Maguire, Adetoun Okenla, Tamara Roldon Sevilla, David Kubiak, Cassandre Titus, Movita Harrigan, Maria Alvarado, Rose Theodat, Amy Sherman, Laura Platt, Kirsten Goodman, Laura Nicholson, Wilfredo Matias, Emily Koleske, Ruth Rodriguez, Nicole Taikeff, Jun Bai Park Chang, Julia Klopfer, Phoebe Cunningham, Elizabeth Sampson, Karen Magsipoc, Maureen Macgowan, Lauren Donahue, Haley Schram, Noah Abasciano, Megan Powell, Janet Morgan, Yazed Alsowaida, Olivia Riccardi, Neha Limaye, Virginia Loudermilk, Austin Kim, Kevin Zinchuk, Caitlin Grant, Charles Kelly, David Mellace, Jamie Myers, Erika Gribb, Jose Licona, Monica Feeley, Stephen R Walsh, Jennifer A Johnson, Ann Woolley, Alexis Liakos, Jane Kleinjan, Jon Gothing, Nicolas Issa, Michael Desjardins, Raphael Dolin, Alka Patel, Opeyemi Talabi, Christin Price, Paulette Chandler, Elizabeth W Karlson, Allison P Moriarty	Brigham and Women's Hospital	Boston, MA
Bindu Balani, MD	Smith Kerowyn, Sergio Garcia, Charo Valdez, Shelly Chin, Caitlin DiBello, Silvia Lara, Chika Ekweghariri, Abena Roberts, Abimbola Coker, Marie-Therese Estanbouli, Greg Eskinazi, Michael Tortoriello, Jay Elkareh, Meral Karakoc, Olga Spathis, Patrice Hassoun, Carolene Stephenson, Steven Sperber, Kaur Harveen, Cristina Cicogna, Ciaran Mannion	Hackensack University Medical Center	Hackensack, NJ
Mira Baron, MD	Pamela Kane, Maria Bermudez, Shannen Seversen, Mara Kryvicky, Julia Lord, Terri Barr, Daisy Acevedo, Elena Acosta, Delta Anderson, Alexandra Arango, Anne Bauer, Joshua Egbehor, Tim Flanary, Audrey Haber, Carol Henao, Patti Isaacson, Peter Jacob, Sakaiya Jackson, Karen Kodes, Ludovic La-Branche, Kimarie Lee- Russell, Carol Liso, Cristina Liso, Stephanie Morse, Michelle Navarrette, Christy Norcross, Nora Norcross, Annette Pitts, Mary Sergalis, David Scott, Tytiana Spearman, Danielle Theodore, Brian Thomas, Jennifer Torres	Palm Beach Research Center	West Palm Beach FL
Judith Borger, DO	Jennifer Angell, Nicole Austin, Deanna Benz, Lucian Cappoli, Nicole Davis, Lynn Eckert, Kathryn Hostetter, Stephanie Keating, Jeanette Mangual-Coughlin, Avia McClain-Stocker, Ifeanyi Momodu, Cheryl Norris, Brennan Opanasenko, Stacey Saldua, Nafisa Saleem, Amy Sheets, Ryan Starr, Scott Syndergaard, Jennifer Thomas, Michelle Wallace, Jeffery Pemberton, Mitchell Arildsen, Dan Tomita	Carolina Institute for Clinical Research	Fayetteville, NC
Paul Simon Bradley, MD	Taja Adams, Stephanie Ailey, Kira Bell, Shanice Bennett, Vincent Bernades, Jim Callis, Bounphone Chanthavong. Taryn Collett, Anne Crouch, Shannon Davis, Morgan Deal, Mimi Duncan, Brandon Essink, Laura Falcone, Debra Gabrielson, Brooke Halpern, Anyfa Hanna, Cassie Heisey, Dawn Kalloniatis, Andrew Kimball, Jeanette Lee, Amanda Lilienthal, Ginny McNew, Crystal Neely, Kay Lynn Olmsted, Nicole Osborn, Chevon Roberts, Pechoka Sanders, Cynthia Seedorf, Kathryn Stoddard, Jonathan Whelan, Stella Yoon	Meridian Clinical Research	Savannah, GA

CoVPN/COVE Team (cont'd): COVE Trial Investigators and Study Teams

Principal Investigator	Study Team	Institution	Location
Adam Benson Brosz, MD	Rhonda Richter, Debra Gabrielson, Kayla Flege, Ashley Bell, Karen Jo Johnson, Paul Cramer, Jessica Stanton, Andrea Clement, Whitney West, Laura Falcone, Amanda Friesz, Kathy Osborne, Summer Tophoj, Kimber Breeden, Susan Newman, Douglas Herbek, Lindsey Mettenbrink, Luke Friesen, Alison Pierce	Meridian Clinical Research	Grand Island, NE
Abram Burgher, MD	Stephanie Catanzaro, Shauna Harrell, Magen Hess, Nate Alderson, Bettie D'Nise Corcoran, Norma Frederick, Adrian Alejo, Brian DeCraene, Karen Wakefield, Scarlett Hammett, Susan DeCraene, Ann Marie Milliken, Neil Pearson, Donald Terral Harper	Hope Research Institute	Phoenix, AZ
Thomas B. Campbell, MD	Andrew Lauria, Jenelynn Kimble, Steven Johnson, Matin Krsak, Andrew Monte, Patrisha Adkins, Michelle Barron, Suzanne Fiorillo, Amy Harrison, Anderson Victoria, Nga Le, Sara Berech, Jose Castillo-Mancilla, Kristine Erlandson, Laurel Ware, Josie Marshall, Stephen Bartlett, Hillary Dunlevy	University of Colorado Denver, Anschutz Medical Campus	Aurora, CO
Shane Glade Christensen, MD	Christopher Mickelson, Jessica Shaw, Emily Raming, Amy Nelson, Gabrielle Lewis, Jenessa Folsom, Mikaela Jones, Dylan Owen, Rachel Pugmire, Jennifer Bradley, Annjanette Kemp, Krista Marti, Allyson Christensen, Madison Ellis, Holly Anderson, Emily Bloomquist, Ross Brunetti, Thomas Conner. Jr., Gina Cox, Diana Grazulis, Wesley Lewis, James Longe, Christopher Matich, Bryan Nelson, Sarah Scott, John Witbeck, Stephen Wood	J. Lewis Research	Salt Lake City, UT
Laurence Chu, MD	Jennifer Bacchi, Maria Barrientes, Lamar Box, Christian Casas, R. Michelle Chouteau, Katherine Davis, Tambra Dora, Cindy Duran, Pamela Fidler, Ruth Fitch, Brooke Harris, Isaiah Knight, Jennifer Leyva, Michelle Listz, Jennifer Montes, Javier Perez, Jessica Ruff, Dean Skiles, Sean Turnbow, Francesca Vigil, Breana Wade, Kelly Weber	Benchmark Research	Austin, TX
Jesse L. Clark, MD	Sandy MacNicoll, Somaieh Talebi, Timothy Hall, Steven Shoptaw, Emery Chang, Michael Li, David Goodman, Paul Adamson, Oladunni Adeyiga, Inez Bentancourt, Susan Reed, Christopher Blades, Jasmin Tavares, Demetria Villanueva, Simone Riley, Jonathan Veloz, Schuyler Thomas, Will Hernandez, Jennifer Baughman, Mitchell Stern, Michele Vertucci	University of California, Los Angeles	Los Angeles, CA
Michael J. Cotugno, MD	Kyra Lawson, Kim Harper, Edwin Adamson, George H. Bauer Jr., Julie Bilich, Brenda Lawson, Brandon Illickal, Lois Eaglin, Heather Salisbury, Jeff Segner	Benchmark Research	Metairie, LA
Clarence Buddy Creech II, MD	Shanda Phillips, Naomi Kown, Katherine Sokolow, Wendy Winn, Katherine Wright, Shannon Walker, Stephanie Rolsma, Anna Gallion, April Hanlotxomphou, Deborah Myers, Robert Adkisson, Natalia Jimenez, Cindy Trimmer, Roberta Winfrey, Matthew Donio, John Oleis, Donna Torr, Shelly McGehee, Robert Samuels, Sandra Yoder, Eric Brady, Isaac Thomsen, Madeleine Guy, Emma Alexander, Lana Howard, Krisha Alexander, Shane Moore, Tacora Wright, Tara Evans, Ursula Powell, Jenna Caserta, Valerie Mitchell, Meryk Moore, Melissa Lehman, Diane Anders, Constance Dotye, Crystal Rice, Lamar Bowman, Sherri Hails, Monique Bennett, Nicki Soper, Leigh Howard	Vanderbilt University Medical Center	Nashville, TN
Joseph D. Davis, MD	Sandra Kelman, Sandra Braden, Sabrina Bolland, Mia Munoz, Jose Barocio, Brendan Levy, Dhwani Shah, Neil Pearson, Stephanie Catanzaro, Nathan Alderson, Susan DeCraene, Maureen Godfrey, Skyla Clark	Hope Research Institute	Chandler, AZ
Luis I. De La Cruz, MD	Amy Ford, Taylor Wilson, Cindy Smith, Austin Lambert, Erin Zeiler, Kaelyn Rowland, Marlee Smith, Suzanna Studdard, Zandra Hamilton, Meredith Benfield, Sara Poff, David Godwin, Elizabeth Everette, Steven Clemons, Kayla Peay, Stephanie Gilreath	VitaLink Research	Greenville, SC
Douglas Scott Denham, DO	Thomas Weiss, Parke Hedges, Ayoade Avworo, Kay Scroggins, Leisel Koerber, Antonio Gutierrez, Nathan Cortez, Andrea Gomez, Darlington Akahara, Michelle Smith, Kristy Trevino, Beatriz Herrera, Shaiane Dickerson, Kerry de Jesus, Matthew Korte, Cynthia Ramos, Reanna Martinez, Erica Leal, Shakera Flores, Paul Esparza, Brian Hemming, Melinda Axton, D'Andre White, Terri Perez, Carolina Coronado, Rebecca Many, Clayton Stone, Kimberly Evans, Anshumaan Maharaj, Stephen Brick, Steffanie Barrera, Staci Poettgen, Dawn Killian, Gerardo Pena, Karol Perez, Victoria Hemandez, Kevin Martinez, Amy Griffith, Nolan Payton, Quincey Hogue, Jamie Padilla, Emily Mendez, Lily Hays, Maristelle Co, Nicholas Trinidad, Ismael Rodriguez, Amy Lewis, Cindi Nellis, Lele Simmons, Marissa Johnson	Clinical Trials of Texas	San Antonio, TX
David Joseph Diemert, MD	Linda Witkin, Aimee Desrosiers, DeEnna Wedding, Bertran Walton, LaKeisha Queen, Ryan Mouton, Caroline Thoreson, Manya Magnus, Jennifer Wald, Erika Faust, Nicholas Heredia, Robbie Kattappuram, Hira Qadir, Chelsea Ware, Hannah Yellin, Kegan Dasher, Daniel Mullen, Jeanne Jordan, Taylor Ladson, Madison Lintner, Kaitlyn Macnair, Bitana Saintilma, Kelly Thomas, Samantha Walker, Neha Rampally, Madhu Balachandran, Elissa Malkin, David Parenti, Hana Akselrod, Marc Siegel, Gary Simon, Afsoon Roberts, Aileen Chang	George Washington University	Washington, DC

Principal Investigator	Study Team	Institution	Location
Susanne Doblecki- Lewis, MD	Maria Luisa Alcaide, Jose Gonzalez-Zamora, Stephen Morris, Yimy Puerto, Annie Salvarrey, Claudia Balgas, Claudia Santos, Katherine King, Brahian Steven Erazo, Mayra Fernandez, Leopoldo Cordova-Garcia, Elisa Corzo- Sanchez, Edgar Fernandez, Loreta Padron, Stefani Ann Butts, Kenia Moreno, Juan Casuso, Maria de Pilar Valanzasca, Thomas Tanner, Marilyn Fernandez, Mary Aloise, Inza Patton, Vivian Pastrana, Sendy Puerto, Irma Barreto Ojeda, Junlin Long, Barbara Huang, Gilianne Narcisse, Vanessa Perez	University of Miami	Miami, FL
Matthew W. Doust, MD	Denise Sample, Sandra Erickson, Nate Alderson, Adrian Alejo, Stephanie Catanzaro, Susan DeCraene, Cassie Enricco, Sandra Erickson, Alex Guereque, Shauna Harrell, Shana Harshell, Stephanie Junker, Stephanie Laufenberg, Madison Mikulak, Makayla Morra, Nicole Olson, Neil Pearson, Jasmin Redden, Monique Romo, Denise Sample, Dhwani Shah, Sahara Vega, Emma Kar	Hope Research Institute	Phoenix, AZ
Valentine Mbepson Ebuh, MD	Elwaleed Elnagar, Georgette Ebuh, Genevieve Iwuala, Catina Adams, Marissa Cervenka, Ezgar Del Real, Shraddha Dubal, Elwaleed Elnagar, Jenifer Fiatte, Kathy Harrell, Genevieve Iwuala, Vicki Martinez, Robert Miranda, Brennan Opanasenko, Destiny Robinson, Liz Ruiz, Amy Sheets, Shoniece Wallace	WR-Global Medical Research	Dallas, TX
Frank Steven Eder, MD	Ryan Little, Victoria Engler, John Tarbox, Heather Rattenbury-Shaw, Deborah Hubish, Jessie Taylor, Debra Gabrielson, Jessica Fellows, Jennifer Molstead, Kathe Olmstead, Ashley Conover, Tammy Kohn, Chelsea Briar, Corrine Young, Collen McVannan, Kelli Quick, Shaylynne Hubanks, Kimber Breeden, Ann Marie Sampson, Traci Hull, Tarin Gordon, Susan Owen, Kate Macarak, Tonya Rackett, Jacob Blattstein, Partidge Jane Aton, Nicole Croft, Carolyn Grausgruber, Rebecca Miller, Ryan Little, Victoria Engler, John Tarbox, Heather Rattenbury-Shaw, Nathan Kimball, Courtney Heisey, Ginny McNew, Abigail Wine, Cindi VanKuren, Jared Frick, Tammy Dennis, Andrew Kimball	Meridian Clinical Research	Binghamton, NY
Hana M. El Sahly, MD	Jennifer A. Whitaker, C. Mary Healy, Christine Akamine, Wendy A Keitel, Robert L Atmar, Annette Nagel, Sandra Francisco, Thea Marie Cordero, Janet Brown, Jennifer Christensen, Caroline Doughty-Skierski, Connie Rangel, Carrie Kibler, Coni Cheesman, Lisreina Toro, Chanei Henry, Chianti Wade Bowers, Pedro Piedra, Kathy Bosworth, Kayla Burrell, Jesus Banay, Tykel Eddy, Trent Davis, Shetel Anassi, Yvette Rugeley, Olga Rybina-Willis	Baylor College of Medicine	Houston, TX
David Jon Ensz, MD	Pamela Allen, Taylor Bergh, Kimber Breeden, Avery Dunn, Brandon Essink, Debra Gabrielson, Rylea Gulick, Tavane Harrison, Courtney Heisey, Andrew Kimball, Shelby Klaschen, Jessica Knight, Makayla Langston, Meagan Miller, Allie Oplinger, Heather Persinger, Alison Pierce, Kathryn Stoddard, Kayla Sturgeon, Jamie Thompson, Melissa Wiseman	Meridian Clinical Research	Dakota Dunes, SD
Brandon James Essink, MD	Jay Meyer, Frederick Raiser, Kimberly Mueller, Roni Gray, Riley Brockman, Tabitha Campbell, Carrie Essink, Laura Falcone, Roni Gray, Linda Layton, Jay Meyer, Kimberly Mueller, Tiffany Nemecek, Frederick "Fritz" Raiser, III, Jessica Satorie, Chelsea Steinmetz, Nicole Osborn, Cassie Heisey, Maria Nguyen	Meridian Clinical Research	Omaha, NE
Gregory J. Feldman, MD	May-Yin Suen, Brittany Cooksey, Madison Fowler, Sarah Chynoweth, Gary Clemons, Laura Jolly, Charlie Jordan, Heather Allison, Steve Clemons, Amber Brittany Belcher, Allison Kelly, Marsha Gossett, Wendy Taylor, Amy Witt, Kendal Nelson, Jeffrey Witt, Jacqueline Muenzner, Elizabeth Everette, Supinder Channa, Allison Ayers, Joseph Boscia, Farhan Siddiqui	VitaLink Research- Spartanburg	Spartanburg, SC
Carl J. Fichtenbaum, MD	Maggie Powers-Fletcher, Michelle Saemann, Sharon Kohrs, Kimberly Mullins, Lindsay Davis, Moises Huaman, Angela Snyder, Kristin Weghorn, Brenda Miller, Elizabeth Costea, Lisa Schira, Romana Saeed, Helen Shelton, Kathleen Ballman, Laura Browning-Cho, Sherry Donaworth, Chris Goddard, Jeanine Goodin, Elizabeth Niederegger, Lisa Hachey, Tamara Maus, Pam Fletcher, Makayla Bishop, Victoria Straughn, Shaina Homer, Carrie Christofield, Dana Burns, Jason Mayes, Kelly Windholtz, Lisa Proffitt, Faizan Qureshi, Michelle O'Neil, Arustamyan Lisa, Sarah Trentman, Eva Whitehead, Jennifer Baer, Linda Hinds, Jaasiel Chapman, D'Vaughn House, Gary Frazier, Judy Houston, Lisa Altenau, Mary Burns, Dorice Smith, Justin Ragle, Eric Mueller, Cynthia Nypaver, Jaime Robertson, Anissa Moussa, Geronimo Feria Garzon, Sierra Bennett, Marlena Petrie	University of Cincinnati	Cincinnati, OH
Carlos A. Fierro, MD	Mazen Zari, Celia Gonzalez, Natalia Leistner, Mary Easley, Mary Provost, Krista Estrada, Ann Geier, Amy Thompson, Heather Barker, Karol Moore, Kelly Moen, Monica Atwood, Amber Wolf, Brandi Dickerson, Manyvohn Rinehart, Dina Hammine, Angela Eichler, Casey Johnson, Nathan Arthur	Johnson County Clin-Trials	Lenexa, KS
Veronica G. Fragoso, MD	Lisa Holloway, Cecilia McKeown-Bragas, Teresa Becker, Vicki Miller, Leena Mir, Elton Oliveira, Moez Talpur, Enya Rentas-Sherman, Gabriela Maria Becerra, Dewayne Hicks, Robert Krbashyan, Shakira Barr, Ashraf Jafri, Herman Ortiz, Zohair Harianawala, Chandra Tobin, Norma Gonzalez, Saji Perinjelil, Khorshid Amirkhosravi, Tracy Kowalski, Biman Goswami, Waheeda Sureshbabu, Amy Anderson, Berenice Ferrero, Simeen Khan, Chen-Ho Yang, Nazanin Zarinkamar, Scott Ward, Crystal Reese, Miyosha Lewis, Olga Konshina, Lorrian Yates.Joel Cano, Quiana Wilson, Kara	Texas Center for Drug Development, Inc.	Houston, TX

Principal Investigator	Study Team	Institution	Location
	Sikes, Diana Chehab, Joanna Quezan, Maryam Rabbani, Sadaf Batla, Abbyssinia Moges. Diego Carrington, Matthew Joseph, Laura Grissanty, Dean Jang, Dustin McFadden, Misbah Baloch, Elisa Moralez, Abdeali Dalal, Frances Saubon, William Fernandez, Jenny Toress, Blessing Felix, Zain Rizvi		
lan Frank, MD	Annet Davis, Eileen Donaghy, Nicole Sundo, Juan Ramirez, Laura Schankel, Dana Brown, Katharine Bar, Dana Brown, Christopher Chianese, Gillain Constantino, Dovie Watson, Kathleen Degnan, Helen Koenig, William Short, Petra Alexander, Eileen Mergliano, Jie Ho, Michele Wisniewski, Debora Dunbar, Liani Santini-Lopez, Rosemarie Kappes, Angela Cabassa, Tammy Chen, Berry SotoVega, Deborah Kim, Devon Cliett, Kate Kearns, Jillian Baron, Vivian Leung, Florence Momplaisir, Sarah Wood, Tameka Matthews, David Metzger, Richard Tustin	University of Pennsylvania	Philadelphia, PA
Sharon E. Frey, MD	Irene Graham, Getahun Abate, Daniel Hoft, Heather Douds, Cassandra Zehenny, Joan Siegner, Helay Hassas, Kim Cooper, Shirley Dettlebach, Sabrina DiPiazza, Carol Duane, Linda Eggemeyer-Sharpe, Lauren Foreman, Jerry Hutter, Ryan Kerr, Kate Liefer, Tracy Montauk, Karla Mosby, Janice Tennant, Nicole Purcell, Kiana Wilder, Kathleen Chirco, Sharon Irby-Moore, Kathleen Koehler, Melissa Loyet, Thomas Pacatte, Susan Stewart, Azra Blazevic, Tamara Blevins, Chase Colbert, Christopher Eickhoff, Lainey Mejia Jauregui, Keith Meyer, Krystal Meza, Amanda Nethington, Huan Ning, Brittany Williams, Mei Xia, Yinyi Yu, Stanley Doublin, Mary Pat Eastman, Eric Eggemeyer, Mikayla Frye, Michelle Harris, Aleshia McCoy, Donna Duncan, Gwendolyn Tatum, Nicole Purcell, Kiana Wilder, Tammy Grant, Claudia Castillo Paredes, Rong Hou, Jin Wang, Qian Wang, Sarah George	Saint Louis University	St. Louis, MO
Cynthia Gay, MD	David Wohl, Joseph Eron, Jr., Andrew Thorne, Michelle Floris-Moore, Christopher Hurt, David Wohl, Chidinma Okafor, Janette Goins, Ulrike Adam, Ekundayo Nylander- Thompson, Anna Furlong, XinHong Ao, Kathy Guerrero, Melinda Hart, Kathleen Loeven, Rachael Mossey, Esther Speight, Rachel White, Chloe Twomey, Kristen Gray, Miriam Chicurel-Bayard, Susanne Henderson, Patti Vasquez, April Welch, Camille O'Reilly, Maureen Furlong, Noshima Darden-Tabb, Elizabeth DuBose, Marie Oriol, Dynesha Perry, Maria Stetson, Maria Bullis, Shelby Turner, Ebony Harrington, Michael Herce, Suzanne Blevins, Alexander Bradley, Susan Pedersen, Becky Straub, Sandra Barnhart, Felicia Barriga Munante, Nazneen Howerton, Tevnan Keller, Mandy Tipton, Abigail Riddick, Kristi Kirkland, Maggie Harman, Tania Hossain, Centhla Washington, Erin Hoffman, Carolina Pastrana Medina, William Johnson, Samantha Earnhardt, Amy James Loftis, Catherine Kronk, Yaa Ofori-Marfoh, Julie A Nelson, Nicole Maponga, Lina Rosengren-Hovee, William Zhao, Jennifer Thompson, Sarah Law, Holly Milner, Jonathan Oakes, Rachel Cook, Erin Cardot, Oesa Vinesett, Victoria Rucinski, Joy Wannamaker, Tanailly Giralt Smith, Eliza DuBose, Chidinma Okafor	University of North Carolina at Chapel Hill	Chapel Hill, NC
Richard M. Glover, II, MD	ard M. Glover, Cayla Lawless, Jane Martinez, Ragene Moore, Martissa Mueller, Aaron Nouven, Start, Jane Martinez, Barden Martinez, Barden Martinez, Barden Martinez, Bardene Moore, Marissa Mueller, Aaron Nouven, Start, Start, Bardene Moore, Marissa Mueller, Aaron Nouven, Start, St		Newton, KS
Gregory Mark Gottschlich, MD	Melissa Gottschlich, Steven Anderson, Gregory Mark Gottschlich II, Mary Woeste, Kate Harden, Cindy Young, Michael Pordy, Audrius Ruksenas, Lacy Baird, Kim Krogman, Lori Stanton, Melissa Fuson, Mason Urban, Christine Watson, Richard Powell, Mary Smith, Jacob Sekinger, Diamond Russell, Nicole Lim, Mylene Asmar- Rios, Yusef Museitif, Craig Mitchell, Tarik Whitham, Zachary Rutledge, Troy Porter, Andrea Newlands, Jami Ramsey, Mary Frances Curry, Nishay Holloman, Crystal Barket, Michelle Spear, Shelley Mahan, Taeleigha Greene, Zachary Eardley, Gen Moussa, Mary Ann Gottschlich	Kim hard hard New Horizons Cincinnati, OH Porter, Clinical Research stal	
Sinikka L. Green, MD	Julie Hamilton, Alex Fuller, Jeanette Dickhaus, Colleen Jacobson, Triny Cooper, Michelle Jackson, Taylor Evans, Tabitha Judd, Kathryn Alexander, Megan Rosallo, Sikhongi Phuguway, Pohin Dotson, Dana Einley, Michael Vasquez, Cyndi Ecster		Cedar Park, TX
Carl P. Griffin, MD	William Schnitz, Andrea Romero, Kim Hamilton, Raymond Cornelison, Angela		Oklahoma City, OK
Milton Haber, MD	Maria Candelario, Martha Bunnell-Pollak, Lauren Wade, Jackie Ziegler, Deena Ramirez, Perla Avalos, Maria Drada, Jasmine Ali, Jessica McDowell, Kehinde Busari, Patricia Church, Ronald Meza, Marco Vela, Esteban Zurita, Chris Connolly, Ruben	Laguna Clinical Research Associates	Laredo, TX

Principal Investigator	Study Team	Institution	Location
	Del Bosque, Alisha Lutat, Chelsea Fleming, Brett Potthoff, Anita Suri, Cynthia Priester, Brenda Hernandez, Veronica Procasky, Eva Cerreta, Matt Honold, Melinda Rodriguez, Maria Regalado, Jordan Stauffer		
Greg Hachigian, MD	Michael Cancilla, Ricardo Castellanos, Angela Cuellar, Yaman Darmarathne, Shaila Faulker, Yana Gordeyeva, Michelle Hisey, Ashley Jungsten, Kristin Kiersey, Pawandeep Nagra, Nav Nagra-Kooner, Jazmin Nauta, Masaru Oshita, Kenneth Quick, Julie Raygoza, Amanny Sadek, Melisa Tinder, Jhoana Torres, Deborah Murray, Kristen Kiersey		Sacramento, CA
Laurie J. Han- Conrad, MD	Brandon Baldwin, Lucian Cappoli, Tenisha Garcia, Ella Grach, Brenda Grande, Nicolle Mendez, Natalie Moy, Matthew Musikanth, Karen Mylerberg, Brennan Opanasenko, Mark Pulera, Patti Sanchez-Emery, Mireles Sarah, Todd Simmons, Denis Tarakjian	WR-Medical Center for Clinical Research	San Diego, CA
Wayne Lee Harper, MD	Toni Bland, Lori Bridges, Lucian Cappoli, Lisa Cohen, Leah Corts, Annie Craft, James Earnhardt, Lynn Eckert, Aubrey Farray, Laura Hoer, Matthew Hong, Chris Hoyle, Jenee Jiggetts, Brian Joseph, Bradley Killebrew, Kendra Lisec, Lucie Mangala, David Musante, Adnan Nasir, Amanda Olsen, Brennan Opanasenko, Marci Parks, Marion Peoples, Katherine Schuch, Judith Shand, Sabine Ucik, Douglas Wadeson, Barbara Wheeler	M3 Wake Research	Raleigh, NC
Ripley R. Hollister, MD	Jeremy Brown, Brandy Ball, Jeremy Brown, Valerie Dyster, Dalia Jeronimo, Shelby Pickle, Michael Pojezny, Melody Ronk, Kathi Shaw, Bobbi Shofner, Jami Wagner, Meghan York, Jill York	Lynn Institute of the Rockies	Colorado Springs, CO
Lisa A. Jackson, MD, MPH	Marilyn Nguyen, Maya Dunstan, Barbara Carste, Sarah Friend, Diana McFeters, Lynn Gross, Mohamed Ajenah, Jana Ffitch, Audra Mccoy, David Skatula, Susan Lasicka, Kimberly Brinker, Karen Sherwin, Melissa Scheer, Paula Lins, Roger Calvert, Roxanne Erolin, Stella Lee, Vi Tran, Stephanie Pimienta, Bruce Douglas, Lee Barr, Colin Fields, Erika Kiniry, Joe Choe, Janice Suyehira, Joyce Benoit, Michael Witte, Rebecca Lau	Kaiser Permanente Washington Health Research Institute	Seattle, WA
Spyros Andrews Kalams, MD	Greg Wilson, Kyle Rybczyk, Katie Crumbo, Carly Griffin, Latoya Hannah, Amy Kerrigan, Valerie Mitchell, Jenna Caserta, Mary Downey, Nicole Swindle, Shonda Sumner, Amber Massey, Trudy Sullivan, Rita Smith, Cindy Nochowicz, Eric Olson, Christian Warren, Josh Simmons, Dana King, Gwendolyn Rees, Matt Donio, Jesse Case, Keith Richardson, Jarissa Greenard	Jenna Caserta, Mary Downey, Nicole Swindle, Shonda Trudy Sullivan, Rita Smith, Cindy Nochowicz, Eric Olson, mmons, Dana King, Gwendolyn Rees, Matt Donio, Jesse	
Colleen Kelley, MD, MPH	Valeria D. Cantos, Sheetal Kandiah, Carlos del Rio, Christina Bacher, Hannah Huston, Juliet Brown, Divya Bhamidipati, Nithin Gopalsamy, Brittany Lynn Speigel, Elizabeth (Betsy) Hall, Brandon Spratt, Kiran Dhillon, Caitlin Moran, Michael Chung, Felecia Wright, Marcia Peters, Rondell Jaggers, Vanessa Soliman, Ron Gaston, Christopher Foster, Sarah Wiatrek, Bezuayehu Mandefro, Pamela Weizel, Pamela Lankford-Turner, Anandi Sheth, John Gharbin, Catherine Abrams, Philip Powers, Paulina Rebolledo, Christin Root, Tiraje Lester, Sha Yi, Damien Swearing, Fred Ede, Isaac Perez, Kelly Likos, Meen Dhir, Aastha KC, Gabriela Georgial, Tucker Colvin, Nabeel Yar Khan, Valarie Hunter, D'Jamel Young, Felecia Atkinson	Emory University Emory University – Ponce de Leon Atlanta, GA Clinical Research Site	
Christina Kennelly, MD	Jacob Coleman, Brittany Bundeff, Melissa C. Hennessey, Kenneth Owen, Caroline Wilds Wilds, Jennifer Womack, Susan Martello, Chiedza Hooker, Robert Brownlee, Melissa James, Deborah Wesley-Farrington, Lori Whiteheart, Hala Webster, David Framm, Cortney Fretz, Gwyn Gibson, Susan Donahue, Kelly Woodell, Linda McCarty, Jim Vesely, Scott Chatterton, Andrew Ottesen, Enrico Belgrave, Krishna Shah, James Chester Alexander, Brittain Callahan	Javara Charlotte, NC	
Shishir Kumar Khetan, MD	Taja Adams, Tanya Alexander, Tanya Alexaner, Sydney Barmoy, Jake Bart, Kira Bell, Ira Berger, Jemario Blackwell, Priscilla Buahin, Bounphone Chanthavong, Juliana DeVito, Azure Erskine, Brandon Essink, Laura Falcone, Debra Gabrielson, Beau Garland, Barb Geiger, Tiana Oliver, Courtney Heisey, Sucharita Katikala, Andrew Kimball, Heather Lang, Jeanette Lee, Asefa Mekonnen, Devan Myers, Kimberly Nieves, Allison O'Brien, Oyebisi Olanrewaju, Nicole Osborn, Adunola Oshiyoye, Rahul Patel, Alan Pollack, April Poole, Collin Smith, Kathryn Stoddard, Chao Wang, Sean Whelan, Jonathan Whelan, Graciela Zapata, Nan Zhai	Meridian Clinical Researc Rockville, MD	
Murray A. Kimmel, DO	Alexa Diec, Ann Riley, Bette Denmat, Bram Swarr, Christina Raidl, Dania Billman, Denise Dixon, Donald Dawson, Elaine Crudo, James Crowley, Katrina Carlson, Kaylie Worzick, Laura Worth, Lisbeth Gordon, Marion Oliver, Robert Holt, Simmy Pinto, Taylor Atkinson, Traci Mitchell, Lana Ghomrawi, Norma Rokoff	Optimal Research Melbourne, FL	
Judith L. Kirstein, MD	dith L. Kirstein, Jared Bradshaw, Krista Forster, Jeanette Dickhaus, Marcia Bernard, Erica Sanchez, Nikki Abels, Cynthia Kunakom, Vanessa Vandergoot, Jessica Fisher, Carol Remigio, Jourdan Manfred, Erederick Llovd Tiffany Williams, Clarisse Baudelaire, Lovette, Rancho Paseo		Banning, CA
Michael J. Koren, MD	Shannon Trull, Amanda Elwood, Mary Strickland, Ivy Gulliermo, Chistopher Ganzhorn, Sonia Gerardo, Taylor Johnson, Victoria Kaposchansky, Cassie Lawler, Laura Little, Amanda Pratt, Sheldon Warren, Andrea West, Emery Noles, Nathanial	Jacksonville Center for Clinical Research	Jacksonville, FL

Principal Investigator	Study Team	Institution	Location
	Grant, Jillian Agnew, Lori Alexander, Brenda Anderson, Deirdre Arrington, Sara Benner, Lisa Carl, Allison Crain, Nafisa Ishaku, Robert Nix, Sharon Smith, Amber Devries, Sandy Salceiro, Opara Chukwudi, Mikaela Karney-Trull, Ramil Castillo, David Graham, Gail Lowe, Alexander Hill, Carolyn Tran, Jeffry Jacqmein, Darlene Bartilucci, Alpa Patel, Janet Garvey, Mitchell Rothstein, Kenneth Aung-Din, Margaret Gannaway, Arman Mughal, Sandra Fuit, Jolenne Wolfer, Erin Schelhorn, Jacob Wolfer, Madison Martinez, Melissa Parks, Patricia Neal		
Karen L. Kotloff, MD	Matthew Laurens, Milagritos Tapia, Lisa Chrisley, Cheryl Young, Barbara Albert, Robin Barnes, Shernel Barrett, Andrea Berry, Melissa Billington, Shannon Bittner, Colleen Boyce, Faith Pa'Ahana Brown, James Campbell, Regina Carpenter, Jamonie Carter, Ginny Cummings, Brenda Dorsey, Jorge Flores, DeAnna Friedman-Klabanoff, Shirley George, Nancy Greenberg, Hassan Haji, Elizabeth Hammershaimb, Susan Holian, Leslie Howe, Myounghee Lee, Alyson Kwon, Kirsten Lyke, Alma Valle Maldonado, Jennifer Marron, Kaitlin Mason, Monica McArthur, Rosa McBryde, Sherry McCammon, Sandra Molina, Kathleen Neuzil, Daniele Nitkowski, Justin Ortiz, Rekha Rapaka, Mardi Reymann, Toni Robinson, Wanda Somrajit, Mark Travassos	University of Maryland, School of Medicine	Baltimore, MD
Mark E. Kutner, MD	Amanda Colina, Isett Caro, Frances Beltran, Jessie Downs, Jonathan Fernandez, Mariete Renden, Mirnaya Mujica-Alabaci, Susel Figueredo, Yanelis Dominguez, Jaime Blandon, Bryan Ruiz, Leidy Montoya, Edgardo Rodriguez, Jessie Downs, Jason Rothscheld, Janett Acle, Yaime Martinez, Soraya Ricardo, Maria Hernandez Moran, Eloisa Guerra, Heidie Perez, Claudia Rodriguez, Victoria Moreno, Vanessa		Miami, FL
Mimi Van Der Leden, MD, PhD	Chrishea Harvey, Tricia Oyeyemi, Aicha Moutanni, Stephanie Melton, Peta-Gay Jackson Booth, Jennifer Yoon, Gloria Kim, Atanas Filev, Francis Uwandi, Meyling Lopez, Janice Spreitzer, Courtney Gennes, Xiangfei Cheng, Matthew Van Sickle, Nick Bart, Brianne Okunji, Frank Maloba	Optimal Research	Rockville, MD
Michael L. Levin, MD	Brennan Opanasenko, Yajaira Ramos, Shonda Lester, Rebecca Boucher, Shawn Harrell, Shon Boucher, Patti Sanchez, Nina Scharbach, Alex Sanchez, Shyane Raniello, Wendy Guerra, Krystal Tyner, Kimberly Temple, Ruby Ortiz, Daniel Terreault, Amy Kill, Jade Odynski, Adolfo DeLeon, Debbie Carter, Eduardo Rodriguez, Julia Gass, Sara Esparza, Sierra Dansbee, Tammy Harrison, Marcy Kulic, Lucian Cappoli, Mora KIm, Matthew Fenner, Heather Jimenez, Shraddha Dubal, Julie Hussey	WR-Clinical Research Center of Nevada	Las Vegas, NV
Michael Lewis, MD	Nancy Mohler, Mai Pham, Ron Waldorf, Elham Ghadishah, Samantha Feril, Stella Lee, Dzuyen Nguyen, Ruoxiang Wang, Justine Velandria, Benjamin Dreskin, Joseph Yusin, Lauren Vigil, Sara Wong, Suchi Tiwari, Joseph Pisegna, Sunita Dergalust, Wayman Lee, Krissa Caroff	VA Greater Los Angeles Healthcare System	Los Angeles, CA
Gregg H. Lucksinger, MD	Jaleh Ostovar, Craig Koch, Danuel Hamlin, Kelly Chase, Jeanette Dickhaus, Edward Kerwin, Frederick Forde, Allison Alvord, Dawn Stewart, Dan Hamlin, Kevin Parks, Ryan Israelsen, Kary Kelly, Tiffany Smith, Melissa Myers, Ryan Rackley, Audrey Kuehl, Savannah Peterson, Hannah Hall, Jay Weisbart, Alison Dodenhoff, Emily Kelly	Velocity Clinical Research	Medford, OR
Mary Beth Manning, MD	Carol Salango, Alec Ireland, Lisa Hoagland, Jeanette Dickhaus, Toby Briskin, Joan Rothenberg, Michael Gaston, Sharita Tedder-Edwards, Denise Roadman, Megan Sokolowski, Tina Shickluna, Katherine Bielanski, Samantha Hood, Talia Chandler, Brianna Arman, Melinda DeLong, Naqib Ahmad, Karly Tarase, Jade Svoboda, Lisle Merriman, Melisa Sebera, Emma Landskroner, Amy Maroun, Brooke Glivar, Jennifer Gaston, Sarah Dzigiel, Cassiandra Uminski, Karol Sabol, Devan Patel, Nick Zarbo, Briana Jackson, Brian Sharpe, Nicole, Baitt, Kaitlyn Duffy, Gabrielle Jacobs, Ann Czuprun, Tracee Cash, Diamond Ivey, Kaitlyn Rubell	Rapid Medical Research	Cleveland, OH
Kristen Marks, MD	Grant Ellsworth, Tina Wang, Timothy Wilkin, Mary Vogler, Carrie Johnston, Marshall Glesby, Roy Gulick, Ole Vielemeyer, Rebecca Fry, Todd Stroberg, Caitlin Rhoades, Noah Goss, Shaun Barcavage, Valery Hughes, Jonathan Berardi, Caroline Greene, Sarah Galloway, Caique Mello, Ashley Machado, Mia Crowley, Monique Williams, Katherine Fee, Elizabeth DeJesus, Andrew Yu, Minkyung Lee, Susan Herder, Mary Ann Zweibel, Patrice Weller, Antonio Rivera-Lopez, Edward Kenny, Hetal May, Natella Fridman, Parul Shah, Ruby Lee, Venus Fernandez, Victoria Evina, Celine Arar, Byron Bullough, Kinge-Ann Marcelin, Brian Mangano, Jessenia Fuentes, Jiamin Li, Genessi Rodriguez, Catherine Jerry, Nadi Islam, Liqun Cai, Wayne Burns, Akinbayo Caulcrick, Andrika Thomas, Barbara Batog, Guoan He, Sara Yoder, Tamara Crowder, Gianna Resso, Sophia Alvarez, Tahera Begum, Elizabeth Connolly, Roxanne Rosario, Paul Kim, Steven Wang, Vasilika Koci	Cornell Clinical Trials Units - Weill Cornell Chelsea and Uptown	New York, NY

Principal Investigator	Study Team	Institution	Location
Judith Martin, MD	Alejandro Hoberman, Timothy Shope, Gysella Muniz, Sonika Bhatnagar, Kumaravel Rajakumar, Anne-Marie Rick, Peri Unligil, Jennifer Nagg, Melissa Andrasko, Mary Ann Sieber, Jennifer Opal, Lalicia Roman, Spenser Kinsey, Michelle Burke, Matthew Lee, Dominic Kramer, Linette Milkovich, Emily Dougherty, Emily Carney, Shannon Mance, Nader Shaikh, Diana Kearney, Jamie Fries, Lisa Vavro, Shayla Goller	UPMC University Center	Pittsburgh, PA
John W. McGettigan, Jr., MD	Walter Patton, Jennifer Schnider, Riemeka Brakema, Heeten Desai, Mikell Brett Karsten, Patricia Jalomo, Cindy Finch Benoy, Karin Choquette, Jonlyn McGettigan, Yvonne De Los Reyes, Melissa Cozzens, Amanda Hermosillo, Cindy Montgomery, Susan Tarwid, Annette Elzy, Tianna Young, Saysamone Banks, Cristina Fernandez, Damaris Atondo, Zoe Sesma, Norma Barrientos, Maggie Tono, Kisha Adams, JoAnn Wilkins, Arianna Bermudez, Carol Sayer, Julie McDowell, Angelina Navarro, Mercedes Sullivan, Crystal Mata, Sheldon Gingrich, Aaliyah Sestiaga, Gia LongoQuality of Life Medical & Research CentersTucso		Tucson, AZ
Mark Montgomery McKenzie, MD	Tiffany Jewell, Zackery Harmon, Michael Elizabeth, Christy Sweet, Teresa Deese, Catherine Schon, Misti Earwood, Lou Cappoli, Brennan Opanasenko, Lisa Guider, Michelle Forgey, Justian Jarrett, Rachel Scott, Elizabeth Michael, Erica Osmundsen, Andrew Wood, Shelly Brooks, Gisela Heintz, Lilian Nukuna	WR-ClinSearch	Chattanooga, TN
Vicki E. Miller, MD	Sajjad Naqvi, Soofia Masood, Fredric Santiago, Sonia Guerrero, Subhash Koneru, Nirja Shah, Andrea Torres, Ramani Gali, Talha Baig, Heather Leary, Afifah Ayub, Nayab Goher, Patti Tate, Reagen Reed, Muhammad Irfan, Amy Starr, Alefiyah Motiwala, Julia Kenny, Victoria Aguilar, Jessica Arguijo, Insiya Valika, Victoria Aguilar, Jagruti Patel, Anna Pena, Faryal Mahmood, Blanca Gomez, Nancy Torres, Kristyn Latil, Tarori Mark, Laura Djampou, Lindsey Kueng, Marianne Tadros, Mohammad Millwala, Monica Murray, Murtaza Marvi, Shivani Shah, Vanessa Gonzalez, Zohair Harianawala, Zainab Rizvi, Ambily Dileep, Jaquelyn Gonzales, Ragen Powell, Carolina Deandres, Syed Fahad Ali Kazmi, Sandra Natalia Perez, Shannon Amacker, Shiela Varghese	DM Clinical Research	Tomball, TX
Gowdhami Mohan, MD	Rodolfo Barrera, Emma Partin, Kelly White, Ashley Rochester, Charles Thompson, Stefanie Tyson, Ashten Sheriff, Alyssa-Kay Peay, Kayla Corn, Barbara A. Richardson, Kristin Miller, Steven Clemons, Cameron King, Emma Partin, Gary Clemons, Brianna Starr, Danyel Johnson, Taylor Davis, Niki Tyson	VitaLink Research	Anderson, SC
Kathleen M. Mullane, DO, PharmD	David L. Pitrak, Cheryl Nuss, Karen Cornelius, Randee Estes, Amy Luckett, Michelle Moore, Judi Pi, Stephen Schrantz, Jill Stetkevych	University of Chicago	Chicago, IL
Joseph Lee Newberg, MD	Mary Reyes, Nicole Leahy, Victoria Andriulis, Herbert Whinna, Patricia James, Lana Ghomrawi, Carole Kempfer, Miriam Arroyo, Maria Castro, Anna Maddox, Reuben Martinez, Jacquilyn McCormick-Burks, Laura Pearlman, Rosalinda Vazquez, Shaheera Suleiman, Neha Atal, Rosalind Vazquez	Synexus Clinical Research	Chicago, IL
Richard M. Novak, MD	Regina Harden, Maria Schwarber, Michael Pacini, Rebeca Gansari, Margie Villarreal, Stephanie Martin, Michelle Lee, Richard Morrissy, , Taylor Ellis, Samuel Rene, Tara Cobbs, Claudia Preciado, Scott Borgetti, Maximo Brito, Olamide Jarrett, Mahesh Patel, Tracy Cable, Charity Ball, Maryann Holtcamp, Rodrigo Burgos, Sarah Michienzi, Emily Drwiega, Mikayla Johnson, Fischer Herald, Benjamin Ladner, Minseung Chu, Carolyn Dickens, Alfredo Mena Lora, Stockton Mayer, Andrea Wendrow, Habiba Sultana, Nanu Nunwar, David Chan, Marla Schwarber, Khandaker		Chicago, IL
Paul Joseph Nugent, DO	Leonard Singer, Jennifer Jones, April Smith, Georgettea Geuss, Lana Ghomrawi, Christine Bennett, Norma Blevins, Linda Brotherton, Michele Byrd, Krista Doss, Victoria Holden, Christine Hull, Jean Montgomery, Nancy Cipollone, Savanah Torline, Brandon Brown, Meagan Thomas, Katie Ziska, Dana Sias, Hannah Wagner	Synexus Clinical Research	Cincinnati, OH
Jeffrey Scott Overcash, MD	Hanh Chu, Kia Lee, Karla Zepeda, John Rodriguez, Adam Prince, Yashveer Dubbula, Elizabeth Tomatsu Michael Voskanian, Crystle Rajania, Stephanie Ramirez, Claudia Camacho, Lauren Arnett, Kecia Darbeau, Ashley Smith, Kimberly Quillin, Cesar Ramirez, Daniel Robitaille, Erica Sanchez, Allie Davis, Michael Waters, Pat Kappen, Valerie Horne, Thao Vuong, Andrew Dennis, Nikki Abels, Dominique Panis, Richard McQuaid, Whitley Harbison, Erika Trujillo, Andrea Garcia, Jose Jacob Esparza, Carlos Vera, Raquel Taitingfong, Cathy Meza, He Pu, Jackielynn Smith, Shandel Odom, Zahira Nieves, Ashliegh Lindsay, Ariana Nasatka, Jose Cazarez, Nora Martinez, Angela Hunt, Antonio Delgado, Linda Vega, Angela Anorve, Erica Martineli, Melania Riordan, Sylvia Lindholm, Gina Ciezkowski, Grecia Perez, Jacob Pineda,	Velocity Clinical Research, San Diego	La Mesa, CA

Principal Investigator	Study Team	Institution	Location
-	Nathan Tyler, Ranya Salem, Amara Yilmaz, Jessica Gonzales, Zabrina Ruiz, Laura Castillo, Yajaira Contreras, Angelica Guzman, Makenna Orel, Jeffery Alvarez, Gordon Bovee, Roxana Ramirez, Joan Esquivel		
James Todd Peterson, MD	Christopher Mickelson, Madeline Maldonado, Alison Charlton, Ashley Bragg, Sean Hansen, Emily Wilcox, Colby Bostock, Megan Henry, Pam Iwasaki, Bradley Young, Katelyn Walker, Joy Nguyen, Lindsey Bevan, Megan Grimmett, Madeline Grote, Heather Littell, Natalie Bee, Alexander Clark, Shana Eborn, Susan Edwards, Dan Henry, Heather Jackson, Gerald Kelty, Issac Pena-Renteria, Jacqueline Rohrer, Jack Taylor, Brooke Barrick, Ty Henry, Anna Dansie, Kenadie Hamblin	J. Lewis Research	Salt Lake City, UT
Paul Pickrell, MD	Susan Bonner, Blaire Graham, Staci Taggart, Hussain Malbari, Tiffany Lemuz, Ethan Shotton, Andrew Bell, Megan Malek, David Pampe, Carol Ann Linebarger, Michelle Peterson, Brandi Chalman, John Luna, Elizabeth Santellanes, Christina Martinez, Lisa Johnson, Lisa Savage, Melissa Winn, Wendi McKenzie, Eileen Euperio, Stefanie Mott, Paul Menefee, Katie Caballero, Darrell O'Brien, Morgan Schulle, Kate Jurek, Olivia Hapanowicz	Tekton Research, Inc.	Austin, TX
Terry L. Poling, MD	Meenakshi (Kavya) Natesan, Patricia Contreras, Denise Hole, Avi Woods, Jill Hiebert, Melissa Burton, Olivia Eagleson, Laura Holz, Terri Ford, Cindy Thome, Terry D Klein, Gregory Greer, Diandra Henriques, Tracy R Klein, Thomas C Klein, Christa Shue, Gina Young, Brenna Sprout	Alliance for Multispecialty Research	Wichita, KS
Bruce G. Rankin, DO	Jennifer Dittman, Lora Parahovnik, Crystal Paccione, Melissa Hodges, Katina Marchione, Matt Maxwell, Any Dominy, Diana Toney, Andrea Marrafino, Laura Isbell, Leandro Fernandez, Claxton Copeland, Michelle Tutt, Adam VanDeusen, Kevin Feldman, Clark Mason, Tifany Huertas, Over Seijas, Jennifer Cline, Christian Beierschmitt, Ryan Hobbick, Jessica Gilliam, Jeanette de Leon, Iman Mencia, Daniel Layish, Vienna Bauer, Shatonia Fields, Albert Garcia, Carrie Rycort, Tasha Brocato, Marshall Nash, Samantha Watts, Amy Houck-Dominy, Angela Hammerle, Teresa Logsdon, Erika Wierzbicki, Taylor Martin, Ranie Hutchins, Fadhel Alyunis, Gail Lavine, Jeffery Hood, Robert Duran, Michelle Jones, Ginny McClanahan, Heather Jackson, Leandra Fernandez, Douglas Winter, Antonio Rivera, Amber Vasquez, Thais Truffa, Daniel Campbell, Grace Newcomb, Elizabeth Orlando, Steven Shinn, John Hill, Christina Isbell, Dhaneshwar Oomrow, Alicia Cevera	Accel Research Sites	DeLand, FL
Michele Diane Reynolds, MD	Jennifer Bashour, Robert Schmidt, Cynthia Mayeux, Uvoka Huffman, Lisa Nicholson, Jacklyn Newton, Lynn Yauch, Cathy Monroe, Kathleen Carty, Angelica Banks, Taylor Werner, Pamela Echols, Pauline Jackson, Chana Hines, Lorine Cook, Cristina Puig, Patrick Brooks, Jennifer Ruiz, Deanna Bowman, Ladina Garcia	Synexus Clinical Research	Dallas, TX
Rambod Rouhbakhsh, MD, MBA	hsh, MD, Bizabeth Danford, Jeff Repper, Mason Boutwell, Alexycia Washington, Krista Hirth, Meagan Grabel MediSync Clinical Research Hattiesburg Clinic		Petal, MS
Meagan Grabel Renata Dennis, Tigisty Girmay, Michelle Wiles, Sharon Curate-Ingram, Lauren Hewitt, Alexis Ahonen, Mari Hart, Sarah Bechnak, Erin Carter, Lauren Nolan, Daniel Sans Graciaa, Geoffrey Kamau, Easton Beshears, Sy Tran, Mary Atha, Mary Bower, Ghina Alaaedine, Brandy Johnson, Jacob Usher, Eileen Osinski, Erin Scherer, C. Tae Stallworth, Stephanie Ramer, Rose Pope, Esther Park, Francine Dyer, Laura Clegg, Rebecca Gonzalez, Stacey Wheeler, Susan Rogers, Vy Ngo, Vanessa Soliman, Kristen Unterberger, Bernadine Panganiban, Christopher Huerta, Juton Winston, Ali Alvarez, Jianguo Xu, Colleen Kelley, Paulina Rebolledo, Nicholas Scanlon, Jessica Traenkner, Matthew Collins, Hollie Macenczak, Cassie Grimsely-Ackerley, Tiffany Lee, Amy Anderson, Michele Paine McCullough, Hannah Huston, Daniella Carter, Lisa Harewood, Srilatha Edupuganti, Varun Phadke, Mindee Adamson, Jeanne Allen, Debbie Bartenfeld, Lily Berz, Amy Cromwell, Sergio Cruz, Fred Ede, Monica Godfrey, Evan Gutter, Angelle Ijeoma, Sara Jo Johnson, Vinit Karmali, Dean Kleinhenz, Jennifer Kleinhenz, Alexandra Koumanelis, Maranda Leary, Tiraje Lester, Juliet Alise Morales, Shashi Nagar, Julia Paine, Dilshad Rafi Ahmed, Brittany Robinson, Amanda Rosner, Renee Silver, Trevor William Sirajud-Deen, Damien Swearing, Maliya Tolbert, Pamela Turner, Chia Uzuegbunam, Claire Wan, Dongli Wang, Erika Wirnberly, Jean Winter, Joy Winters, Yong Xu, Sha Yi		Emory University - Hope Clinic	Decatur, GA
Richard Rupp, MD	Amber Stanford, Megan Berman, Laura Porterfield, Gerianne Casey, Hala Ghoson, Doreen Jones, Michael Willig, Cori Burkett, Robert Cox, Amy McMahan, Diane Barrett, Kristin Pollock	University of Texas Medical Branch	Galveston, TX
Jamshid Saleh, MD	Matthew Miles, Rafael Lupercio, Vicky Martin, Marla Clark, Matthew Pohlmeyer, Puba		Redding, CA
John W. Sanders, MD, MPH	Stacy Harpe-Hall, Jesse Hopkins, Ann Schweppe, Jaymous Fayssoux, Kathryn Bender, James Peacock, Katharine Pearsall, Brandy Snyder, Deidre Knox, Megan Thorpe, Melissa Ellingson, Brittany Bundeff, Lisa Ashworth, Meredith Hiatt, Ritu Rathee, Stacy Woodliff, Brian Strittmatter, Amanda Wright, Daisy DeWeese-Gatt,	Wake Forest University Health Sciences	Winston Salem, NC

Principal Investigator	Study Team	Institution	Location
	Caryn Morse, John Williamson, Samantha Wheeler, Lori Whiteheart, Susan Donahue, James Lovette, Kaitlyn Van Leuvan, Kelly Ledbetter, Scott Chatterton, Julio Nasim, Amie Sidberry, Ashley Davis, Carter Noecker, Chie Hooker, Johanna Breenan, Sam Cable, Anna Bowman, Stephanie Boothe, Shea Overcash		
Howard I. Schwartz, MD	Carlos Valladares, Jocelyn Morrera, Yulexis Amestoy, Tori Wallenburg, Thelma Beltran, Terry Piedra, Monica Garces, Alexandra Galvis, Wanda Delgado, Catherine Casas, Lesly Miguel Sosa, Vivian Rosales, Jose Fernando Henriquez, Mikael Yaniz, Beatriz Rivera, Peter Ventre, Gabriella Huyke, Maria Companioni, Jessie De Vega, Brianna Gamez, Stephanie Diaz, James Jean-Mary, Americo Padilla, Nikita Notise, Yorlina Luquetta, Monifa Wilson-Morris, Kenia Gutierrez, Roilan Garcia, Karla Pentzke, Leyda Valentin, Lazara Novas, Marilein Camacho, Jazmin Henfield, Laymis Alvarez, Myriam Rosado, Maxine Bryant, Maria Pinero, Laura Raucci, Francisco Ramirez, Angelic Gamez, Mailin Perez, Yasmin Baddour, Hary Leon Joseph, Yaquelin De la Cruz, Dunia Torres, Rosaidaliz Carreira, Chanella Garcia, Surisaday Mederos, Jose Muniz, Karenda Plotka, Sara Gomez, Maria Soto, Cathy Cruz, Nelia Sanchez-Crespo, Jennifer Schwartz, Barbara Corral, Matthew Muniz, Dayana Deltejo, Ana Castro, Reem Hassan		Hollywood, FL
Nathan Segall, MD	Michelle Sowell, Nancy Levine, Erynn McKinley, Hannah Smith, Karen Hickson, Elizabet West, Patrizia Greene, Jon Finley, Mildred Stull, Susan Jones, Jennifer LeBrun, Pamela Talbott, Kwannda Whatley, Jeffrey Jones, Michelle Binns, Donna Toepfer, Cynthia Steele, Grace Newville, Gillian Waite, Cynthia Pinckney, Karen Yangapatty, Kiara Tyner, Kimberly Cobb, Kourtney Richardson	Clinical Research Atlanta	Stockbridge, GA
William Seger, MD	Kimberly Pullen, Jean Seignon, Anthony Kim, Mohammed Antwi, Allison Green, Lizzy Seger, Elizabeth Boydston, Abdur Rafay Qadri, Deborah Devlin, Tasha Todd, Oluwatosin Akingbala, Alma Guel, Tisha Davis, Melody Dufrene, Samantha Loudermilk, Virginia Loudermilk, Crystal Starr, John Villegas, Ben Seger, Katherine Hollie	Benchmark Research	Fort Worth, TX
Neil Parmanand Sheth, MD	Kenneth Stell, David Beckett, Enitt Gonzalez, Donna McGunigal, Amanda Burns, Nancy Wood, Shelley Miceli, Christina Avila, Rebecca Baker, Laura Vigliotti, Sarah Kading, Samer Salama	Synexus Clinical Research	Glendale, AZ
William B. Smith, MD	Richard L Gibson, Jennifer Winbigler, Elizabeth Parker, Madison Watts, Suzann Cloninger, Talya Thomas	r, Madison Watts, Suzann Multispecialty Research	
Joel Solis, MD	Martha Carmen Medina, Xavier Morales, Hank Heller, Blake Torrence, Joanna Gurrola-Mahoney, Cynthia Bueno, Heather Holloway, Irving Salinas, Joel Perez, Paola Garcia, Erica Canales, Blanca Urbina, Brancisilio Gutierrez, Carolina Cantu, Chelsea Vargas, Cindy Vasquez, Cody McIntire, Gabriela Gutierrez, Hugo Sosa, Irvin Munoz, Jessica Estrada, Jonna Lopez, Kaegan Knox, Mirella Melendez, Natalia Valle, Natalie Echavarria, Nicole Litton, Amber Victor, Nancy Torrence, Madhu Shreya, Mathew Maran, Asfak Alam, Westly Keating, Tara Green, Devora Torrence, Gerardo Sedas, Shruti Konda, Prem Jangam, Mario Echavarria, Alejandro Silva, Anne McNulty, Daniel Contreras, Daniel Gomez, Edgar Garcia, Elizabeth Weber, Luis Lopez, Samuel Ramirez, Kayla Lopez, Pedro Penalo, Angel Salinas, Jaime Solis, Shannon Moyer, Aryana Ibarra, Guadalupe Gurrola, Jenna Anastasiades, Uchechi Ehiemua, Sara Solorzano	Centex Studies, Inc.	McAllen, TX
Stephen A. Spector, MD	Amaran Moodley, Jill Blumenthal, Baharin Abdullah, Christina Addington, Juan Carlos Alcantar, Deyna Arellano, Bernadette Cale, Brendan Costello, Tammelita Cotlon- Pineda, Fanny Delebecque, Karen Deutsch, Aram Dimayuga, Son Do, Yasmeen Esshaki, Aileen Everhart, Cindy Ewing, Veronica Figueroa, Medardo Gaytan, Crystal Groom, Carolyn Hernandez, Heather Huitema, Benjamin Hull, Sylvia Isaac, Jaclyn Jaskowiak, Cindy Knott, Leander Lazaro, Thuan Le, Megan Loughran, Michelle Madey, Rosalva Martha-Patten, Colleen McLellan, Jeff Ledford-Mills, Asami Mimura, Patty Moraes, Jennifer Morales, Jessica Nasca, Phirum Nguyen, Marielys Padilla- Martinez, Dennis Perpetua, Mike Pizza, Shannon Ransom, Emily Rizo, Carlos Rojas, Thaine Ross, Marie Sagrado, Eugene Sato, Lisa Stangl, Ji Sun, Nancy Tang, Mina Trivedi, Rodney Trout, Donna Voss, Lindsey Woronicz	University of California, San Diego	La Jolla, CA
Cynthia Becher Strout, MD	Rica Santiago, Yvonne Davis, Patty Howenstine, Alison Bondell, Jaime Robertson, Anissa Moussa, Geronimo Feria Garzon, Sierra Bennett, Marlena Petrie	Coastal Carolina Research Center	Mount Pleasant, SC
Shobha Swaminathan, MD	Amesika Nyaku, Tilly Varughese, Rondalya Deshields, Michelle L DallaPiazza, Elise Lewis, Jennifer Punsal, Mario Portilla, Malithi Desilva, Christina Daliani, Susana Rivera, Aidan Ziobro, Andressa Rebellatto, Brian Murloy, Christina Ninan, Ernest Pianim Funice Wang, Marit Henen, Muhammad Lleman, Bebecca Kim, Shiao Wang		Newark, NJ


Principal Investigator	Study Team	Institution	Location
Ramy Joseph Toma, MD	Olivia Graves, Josiah Robinson, Patricia Hammonds, Lana Ghomrawi, Kara Quinnelly, Shaun O'Conor, Michael Lambe, Rachell Stewart, William Kirby, Pink Folmar, Rachel Culbreth, Heidi Leblanc, Julie McDaniel, Rian Montgomery, Andrea Woodle, Samantha Williams, Hunter Russell, Shereen Lowe, Maureen Mayer, Hollis Ryan, Elaine Reese	Synexus Clinical Research	Birmingham, AL
Timothy P. Vachris, MD	Mark Hutchens, Stephen Daniels, Margaret Wells, Sandra Clancy, Rebecca Martinez, Jessica Buot, Merissa Daugherty, Julie Hamilton, Kimberly Hernandez, Ashli Alejandro, Amy Collins, Monique Gawlik, Patricia Johnson, Maria Moreno, Ashley Washington, Tina Rountree, Daniel Dore, Ravi Davuluri, Ashlee Brunaugh, Jorge Martinez, James Hermon, Vianai Carreno, Mia Rountree, Colleen Coelho	Optimal Research Austin, TX	
Keith William Vrbicky, MD	Charles Harper, Chelsie Nutsch, Wendell Lewis III, Cathy Laflan, Linden DeBoer, Kayla Andal, Misty Appeldorn, Jenniger Grebe, Russell Herstein, Catherine King, Samantha Wieseler, Alisha Kiepke, Christy Lee, Kelsey Kelley, Kelli James, Ashley Frisch, Courney Green, Taysha Hingst, Jeni Hoppe, Kimber Breeden, Debra Gabrielson, Ginny McNew	Meridian Clinical Research	Norfolk, NE
Larkin T. Wadsworth III, MD	Ashley Dale, Christy Schultz, Rebecca Munsch, Anya Penly, Liz Garner, Stephanie Tesson, George Cherniawski, Angie Kean, Dan Reed, Courtney Kubiak, Maureen Dempsey, Heather Cherniawski, Breanna Galibert, Kristin Branson, Laura Hartupee, Karen Knapp, Horacio Marafioti, Lyly Dang, Jennifer Berry, Lauren Clement, Megan Dandurand	Sundance Clinical Research	St. Louis, MO
Jordan L. Whatley, MD	Patricia Whatley, Christopher Dedon, Anika Payne, Amie Shannon, Kristen Losavio, Nicole Harrell, Mary Margaret Dobson, Lindsey Hall, Chaney Bennett, Crystal Rowell, Mimi Dimmick, Amy Thomassie, Kimber Breeden, Cody LaFleur, Makaylea Truitt, Taryn Collett, Emily Best, Alexandra Caillouet,	Meridian Clinical Research	Baton Rouge, LA
Judith White, MD	Amy Edridge, Chelsea Montalvo, Eugenia Clark, Lisa Russell, Zahra Somji, Lesli Leimer, Robert Meyer, Christine Murphy, Prity Patel, Sejal Patel, Ruben Moliere, Samantha Merveillard, Yarnick Mirjah, Bryn Walls, Joey Cruz, Aaron Cooper, Jessica Bienaime, Ashley Gilcrist, Alisa Petit, Tyler Knightly, Kimberly Stokes, Christina Rosario, Talhia Matos, Ilona Boggs, Nicholas Weber, Felix Busot, Linda Colon, Heather Gillenwater, Cristina Kaplun, Melissa Caputi, Shayna Siplin, Daminee Shah, Samuel Martin, Alexis Waldorf, Vihar Upadhyay, Adolfo Henriquez, Saskia Singh, Maria Roberts, John Caporelli, Shirley Salvador, Quevina Scarver, Vanessa Garcia, Taylor Moore, Jayasen Singh, Curshinda Galvin-Burch, Mary Kesner, Jasmin Gil, Shay Gray, Steven Monsegur, Michele Steinmetz, Michael Lambe, Heather Powell, Sandra Torres, Shaban Katbeh, Taylor Wilson	Synexus Clinical Research	Orlando, FL
Priyantha N. Wijewardane, MD	Natalie Johnson, Martha Evans, Sondra Wright, Richard Pellegrino, Lastida Burns, Natasha Williams, Haylee Rowe, Kayla Graham, Amanda Horn, Eric Bravo, Jeffrey Thessing, A. Michele Maxwell, Amy Cooper, Lauren Evans, Tonya Cato, Haylee Tucker, Lesa Gann, Hannah Jones, Amanda May, Tiffany Walker, A. LeiAn Diaz, Laura Khalil, Lydia Purcell, Timothy Campbell, Charlotte Garcia-Velez, Andrea Scarborough, Beatrice A. Miller, Keith Bracy, Aujania Thompson, Cassandra Johnson, Krishana Day, Freddie Hicks, Jamie Pettus	Baptist Health Center for Clinical Research	Little Rock, AR
Barton G. Williams, MD	Flo Abbott, Nicole Burton, Alice Cipollini, Madison Croucher, Philip Dattilo, Erin Harrelson, Kelsey Heston, James Ingram, William H Jones, Karla Lane, Brandy Lowman, Evan Lucas, Megan Marles, Morgan Mathis, Angie Northcott, Clyda Pasquantonio, Alyssa Valente, Ciara Winders, Stephanie Graham	Trial Management Associates	Wilmington, NC
Marcus J. Zervos, MD	Paul Kilgore, Mayur Ramesh, Jelena Verkler, Pardeep Pabla, Andrew Clark, Katrina Williams, Dee Dee Wang, Beverley Duthie, Samia Arshad, Alandra White, Anna Kern, Ashley Mattern, Bilqis Mosed, Dana Parke, Doreen Dankerlui, Dragana Spasevska, Hanah Woods, Helina Misikir, Howard Klausner, Janay Scott, Jessica Heinonen, John Zervos, Joseph Miller, Kate Zenlea, Kristin Eis, Marissa Vasquez, Maurice Slaughter, Meaghan Flynn, Michael Garcia, Michelle Sankah, Nina Paeilli, Philip Benson, Robert Devore, Stevanya Baho, Tony Eljallad, Tyler Prentiss, Yaman Ahmed, Sharon Mathys, Linda Kaljee, Jeffrey Van Laere, Claudia Hanni, Hassan Zafar, Mona Desai, Gina Maki, Mary Perri, Dora Vager, Shannon Thomas, Autumn Robinson, Isis Hamilton, Sonia Eliya, Jehan Jazrawi, Biljana Popovic, Sharon Zahul, Joshua Ruzzin, John Laguio, Ali Mathena, Bobby Cook Jr., Marlene Hesler, Rochelle Fleming, Terria Minniefield, John Simons, Sherese Henderson, Ashley Hopkins, Rebecca McFarlane, Raeshell Carson, Jonathan Williams, Katherine Reyes, Erica Herc, Indira Brar, Mayur Ramesh, John McKinnon, Lacquis Duncan, Tim Asmar, Margaret Beyer, Kaleem Chaudhry, Madison Lee, Jo-Ann Rammal, Karthik Sridasyam, Siddesh Veer, Angelique Buluran, Kimberlyn Lott, Jeremiah Rooker, Alayna Wilder, Kathleen Wilson, Allison Weinmann, Hassan Mourtada	Henry Ford Health System	Detroit, MI

United States Government (USG)/Coronavirus Prevention Network (CoVPN) Biostatistics Team. (PubMed listed, and ordered alphabetically by institution affiliation)

Affiliation	Team Members
Biomedical Advanced Research	Di Lu, James Zhou
and Development Authority	
(BARDA), Washington, DC	
Department of Biostatistics and	David C. Benkeser
Bioinformatics, Rollins School	
of Public Health, Emory	
University	
Vaccine and Infectious Disease	Jessica Andriesen, Bhavesh Borate, Lindsay N. Carpp, Andrew
Division, Fred Hutchinson	Fiore-Gartland, Youyi Fong*, Peter B. Gilbert*, Ying Huang*,
Cancer Research Center, Seattle,	Yunda Huang, Ellis Hughes, Ollivier Hyrien, Holly E. Janes*,
WA	Michal Juraska, Yiwen Lu, April K. Randhawa, Brian Simpkins,
	Brian D. Williamson, Lars W.P. van der Laan, Chenchen Yu
Biostatistics Research Branch,	Michael P. Fay, Dean Follmann, Martha Nason
NIAID, NIH, Bethesda, MD	
Division of Biostatistics, School	Nima S. Hejazi
of Public Health, University of	
California, Berkeley, CA	
Department of Biostatistics,	Marco Carone, Kendrick Li, Wenbo Zhang
University of Washington,	
Seattle, WA	
Department of Statistics,	Alex Luedtke
University of Washington,	
Seattle, WA	
Department of Population Health	Iván Díaz
Sciences, Weill Cornell Medical	
College, New York, New York	

*YF, PBG, YH, and HEJ are also affiliated with the Department of Biostatistics, University of Washington, Seattle, WA.


Figure S1. Timing of mRNA-1273 doses, blood sampling, and the two time periods for diagnosis of COVID-19 endpoints ("Intercurrent" and "Post Day 57"). The schematic applies to baseline SARS-CoV-2 negative per-protocol recipients of two doses of mRNA-1273.



For Baseline Negative Per-Protocol recipients of two doses of mRNA-1273:

¹Intercurrent Endpoints: \geq 7 days post Dose 2 through 6 days post Day 57; used in Day 29 marker correlates analyses only ²Post Day 57 Endpoints: \geq 7 days post Day 57; used in Day 29 and in Day 57 marker correlates analyses

Figure S2. Flowchart of study participants from enrollment to the case-cohort set of baseline SARS-CoV-2 negative per-protocol participants.



1 If a participant had multiple reasons for exclusion from the Per-Protocol Set, they were only counted in the earliest-listed reason

2 Baseline SARS-CoV-2 positive is defined as immunologic or virtual of prior COVID-19 (i.e. a positive nasopharyngeal swab and/or binding antibodies against SARS-CoV-2 nucleocapsid above the limit of

detection or above the lower limit of quantification) at Day 1 before the first dose of investigational product (same definition as in Baden et al. 2021). 3 The other reasons for exclusion were: did not receive second dose; received incorrect vaccine; received dose 2 out of window; other major protocol deviations; were living with HIV; adjudicated COVID-19 cases up to Day 29 visit (dose 2 date).

4 Minority includes Blacks or African Americans, Hispanics or Latinos, American Indians or Alaska Natives, Native Hawaiians, and other Pacific Islanders, Non-Minority includes all other races with observed race (Asian ⁵ Participants 18-64 were categorized as "At-Risk" (of severe COVID-19 illness) if they had at least one of the following risk factors: chronic lung disease (e.g., emphysema, chronic bronchitis, idiopathic pulmonary fibrosis, cystic

¹ Participants 18-64 were categorized as AL-Nak (or severe COVID-19 limitess) in they not at least one or the following risk factors, chronic limit and a sease (e.g., herphysema, chronic bronchilds, lidopatinc pulmonary inorosis, cyster fibrosis, or moderate-to-severe asthma); cardiac disease (e.g., heart failure, congenital coronary artery disease, cardiomyopathies, or pulmonary hypertension); severe obesity (BMI ≥40); diabetes (type 1, type 2, or gestational); liver disease; or HIV infection (same as in Baden et al. 2021). ⁶ Correlates analyses of Day 29 markers start counting COVID-19 endpoints at 7 days post Day 29 visit, and correlates analyses of Day 57 markers start counting COVID-19 endpoints at 7 days post Day 57 visit. ⁷ Almost all of the antibody levels for placebo recipients were negative, as expected given restriction to participants without evidence of prior SARS-CoV-2 infection. These antibody data were not included in correlates analyses as they do not contribute value except for veritying low false positive rates of the assays.

Supplementary Text 1: Additional details on the immunoassays

Solid-phase electrochemiluminescence S-binding IgG immunoassay (ECLIA)

MSD SECTOR® plates were precoated by MSD with SARS-CoV-2 spike (S-2P), receptor binding domain (RBD) protein, Nucleocapsid (N) protein and a Bovine Serum Albumin (BSA) control in each well in a specific spot-designation for each antigen. The assay was performed with a Beckman Coulter Biomek based automation integration platform including the Biotek 405TS Plate Washer. Serum samples were heat-inactivated for 30 minutes at 56°C prior to assay. Plates were blocked for 60 minutes at room temperature (RT) with MSD blocker A solution without shaking. Plates were washed and MSD reference standard (calibrator), QC test sample (pool of COVID-19 convalescent sera) and human serum test samples were added to the precoated wells in duplicates in an 8-point dilution series. Reference standard was added in triplicates. MSD Control sera (low, medium and high) were added undiluted in triplicates as per validated assay format. Additional assay controls might be added in triplicates. Samples were incubated at RT for 4 hours with shaking on a Titramax Plate shaker (Heidolph) at 1500 rpm. SARS-CoV-2 specific antibodies present in the sera or controls bound to the coated antigens. Plates were washed to remove unbound antibodies. Antibodies bound to the SARS-CoV-2 viral proteins were detected using an MSD SULFO-TAGTM anti-human IgG detection antibody incubated for 60 minutes at RT and with shaking. Plates were washed and a read solution (MSD GOLDTM read buffer) containing electrochemiluminescence (ECL) substrate was applied to the wells, and the plate was entered into the MSD MESO Sector S 600 detection system. An electric current was applied to the plates and areas of well surface which form antigen-anti human IgG antibody SULFO-TAGTM complex emitted light in the presence of the ECL substrate.

The MSD MESO Sector S 600 detection system quantitates the amount of light emitted and reports the ECL unit response as a result for each test sample, control sample and reference standard of each plate. Analysis was performed with the MSD Discovery Workbench software, Version 4.0. Calculated ECLIA parameters to measure binding antibody activities include interpolated concentrations or assigned arbitrary units (AU/mL) read from the standard curve. Recently the arbitrary units were bridged to the WHO International Standard and a conversion factor was calculated and confirmed. Parallelism was established for all three antigens between the MSD provided reference standard and the WHO provided international standard. Concentration assignments were performed and then confirmed both at MSD and as part of a multi-site confirmation study. Sample results reported here have been converted to international units (IU/mL).

Neutralization assay

The neutralization assay was performed as detailed in Shen et al.¹ Briefly, spike-pseudotyped virus was prepared by transfection in 293T cells using a lentivirus backbone vector, a spike-expression plasmid, a TMPRSS2 expression plasmid and a firefly Luc reporter plasmid. A pre-titrated dose of pseudovirus was incubated with eight serial 5-fold dilutions of serum samples (1:10 start dilution) in duplicate in 96-well flat-bottom poly-L-lysine-coated culture plates for 1 hr at 37° C prior to adding 293T/ACE2 cells. One set of eight wells received cells + virus (virus control) and another set of eight wells received cells only (background control). Luminescence was measured after 66-72 hr of incubation using Promega 1X lysis buffer and Bright-Glo luciferase reagent. Neutralization titers are the inhibitory dilution of serum samples at which relative luminescence units (RLUs) were reduced by either 50% (ID50) or 80% (ID80) compared to virus control wells after subtraction of background RLUs. Serum samples were heat-inactivated for 30 min at 56°C prior to assay.

Calibrated neutralization titers (cID50 and cID80)

Results from the neutralization assay are reported as calibrated ID50 (cID50) and calibrated ID80 (cID80) titers. The calibration was conducted for the First WHO International Standard for Anti-SARS-CoV-2 Immunoglobulin (20/136) in the SARS-CoV-2 spike-pseudotyped virus neutralization assay in 293T/ACE2 cells. The reagent is intended to be used in part to normalize neutralization titers across multiple SARS-CoV-2 neutralization assays (SOP CFAR02-A0026 "Measuring Neutralizing Antibodies Against SARS-CoV2 Using Pseudotyped Virus and 293T/ACE2 Cells" from the Duke Montefiori lab). The calibration work was performed by the "Neutralizing Antibody Core" Laboratory in the Surgical Oncology Research Facility, under the GCLP oversight of the Quality Assurance for Duke Vaccine Immunogenicity Programs (QADVIP).

Reagent description. In December 2020, the WHO released a well-characterized international standard for the purpose of improving comparability of results among different assays in different laboratories and reducing interlaboratory variability of anti-SARS-CoV-2 antibody assays.² As described in the user instructions provided by the National Institute for Biological Standards and Controls (NIBSC): "The First WHO International Standard for anti-SARS-CoV-2 immunoglobulin is the freeze-dried equivalent of 0.25 mL of pooled plasma obtained from eleven individuals recovered from SARS-CoV-2 infection. The preparation was evaluated in a WHO International Collaborative study. The intended use of the International Standard is for the calibration and harmonization of serological assays detecting anti-SARS-CoV-2 neutralizing antibodies. The preparation can also be used as an internal reference reagent for the harmonization of binding antibody assays. The preparation has been solvent-detergent treated to minimize the risk of the presence of enveloped viruses".³

Reagent preparation and storage. The reagent was shipped as a lyophilized powder by the NIBSC on December 23, 2020 and was received at Duke on January 4, 2021. A second shipment of the lyophilized reagent was received from the NIBSC on March 15, 2021. The reagent was stored at -80°C upon arrival. Each vial of lyophilized reagent was reconstituted with 0.25 mL of sterile distilled water (Invitrogen, Cat No. 10977015, Ultra-pure DNase, RNase free, Lot 2186762, Exp 30-Aug-2022) as described in the instruction packet³ and stored at 4°C until use (no longer than 4 weeks).

Protocol and assay results. Neutralization assays were conducted in accordance with SOP CFAR02-A0026 "Measuring Neutralizing Antibodies Against SARS-CoV2 Using Pseudotyped Virus and 293T/ACE2 Cells" using the spike pseudotyped virus CoV-2 VRC7480.D614G.1[CMVAR8.2]/293T/17. The assays were performed between January 5, 2021 and April 16, 2021 by four operators. All assays used either a 1:20 or 1:30 start dilution and a 5-fold dilution series for a total of 8 dilutions. One vial of the standard was reconstituted on January 5 and assayed once on each of 10 plates in a single setting by a single operator (EY) on January 5, 2021; the plates were read on January 8, 2021 (Exp ID EY18-134 in Table 1). These 10 assay results were described in Duke-02-MVR-COVID0001.2. In response to FDA/CBER recommendations (MF 026862, comments dated March 1, 2021), additional assays were performed over different operators and days to yield more precise estimates of the calibration factors. Additional vials of the reagent were reconstituted on March 20, 2021 and assayed in quadruplicate by two operators on two days. A third operator assayed the reconstituted standard in quadruplicate on 3 days. All assays were set up within 24 days of reconstitution. The WHO assigned an arbitrary unitage of 250 IU/ampoule (1000 IU/mL) for neutralizing activity. For calibration purposes, ID50 and ID80 titers may be converted to IUs by dividing 1000 IU/mL by either the mean, median or geometric mean ID50 and ID80 titer as a dilution factor. Thus, the calibration factor for mean ID50 is $1000 \div 4135 = 0.242$. The calibration factor for mean ID80 is $1000 \div 666 = 1.502$. The calibration factor for median ID50 is $1000 \div$ 2422 = 0.413. The calibration factor for median ID80 is $1000 \div 489 = 2.045$. The calibration factor for geometric mean ID50 is $1000 \div 3047 = 0.328$. The calibration factor for geometric mean ID80 is $1000 \div$ 567 = 1.764. The calibration factors are summarized in the following table:

SUMMARY VALUES FOR WHO ANTI-SARS-COV-2 IgG (20/136)			
Virus: SARS-CoV-2 D	614G Variant	Calibration Factor	
Arithmetic mean ID50	4135	0.242	
Arithmetic mean ID80	666	1.502	
Median ID50	2422	0.413	
Median ID80	489	2.045	
Geometric Mean ID50	3047	0.328	
Geometric Mean ID80	567	1.764	

The three types of calibration factors (based on arithmetic mean, median, and geometric mean) were compared head-to-head on validation data from Day 29 and Day 57 ID50 and ID80 values from 30 recipients of the mRNA-1273 vaccine, with the common samples conducted by both the Duke Montefiori neutralization assay used for the COVE trial immune correlates study and the Monogram PhenoSense neutralization assays. The results showed that using arithmetic mean of the WHO IS sample for calibration yielded the highest agreement between the calibrated vaccine responses from the two labs, based on the concordance correlation coefficient (manuscript in preparation). Based on this validation experiment, the arithmetic mean calibration factors were selected for use in reporting results in terms of cID50 and cID80 titers.

Calibration of ID50 and ID80 titers between the Duke neutralization assay on COVE trial samples and the Monogram PhenoSense neutralization assay performed on AZD12222⁴ samples

Using the WHO First Anti-SARS CoV-2 Immunoglobulin International Standard (20/136): 1000 IU/mL, PhenoSense SARS CoV-2 nAb titers can be converted to IU/mL by multiplying the nAb titer (ID50 or ID80) by the appropriate conversion factor (D614G pseudovirus). Conversion factors were calculated using the mean, geometric mean and median based on 24 replicate tests of the 20/136 standard (6 replicates per day x 4 days). Based on the validation data noted above the arithmetic mean conversion factor was used. The conversion factors for ID50 and ID80 were 0.0653 and 0.2281, respectively. To illustrate how these conversion factors were applied, the ID50 values reported in Table 2 of Feng et al.⁴ corresponding to 70% and 90% estimated vaccine efficacy were multiplied by 0.0653. Specifically, the ID50 values 57, 183, 982, 303 reported in Table 2 were each multiplied by 0.0653 to obtain cID50 values 4, 12, 64, 20, respectively; these values are reported in the Discussion of the present COVE trial correlates manuscript. Note that the Monogram PhenoSense neutralization assay performed on AZD12222 samples used the original ancestral D614 strain, whereas the Duke neutralization assay performed on COVE samples used the D614G strain. Because of this, the conversion factor 0.0653 was selected as the factor derived for the D614G strain.

	MSD Binding Assay (VRC)		PsV nAb (Duke)		
Reported units	IU/ml*		Calibrated titers**		
	Spike	RBD	Ν	cID50	cID80
Positivity Cutoff	10.8424	14.0858	23.5	2.42	15.02
LOD	0.3076	1.5936	0.09	2.42	15.02
LLOQ	1.7968	3.43	4.49	4.477	21.4786
ULOQ	10,155.95	16,269	575	10919	15368

Table S1. Meso-Discovery (MSD) and pseudovirus neutralization assay limits of the four antibody markers evaluated as immune correlates.

*AU/ml units converted to IU/ml units for all data analysis. VRC report "Conversion of SARS-CoV-2 Binding Assay Results from Arbitrary Units to WHO International Units" (report March 30, 2021)

IU/ml limits and positivity cut-offs collated in June 2, 2021 VRC report "Moderna 4Plex Data Upload and Analysis Parameters" (Sarah O'Connell at VRC).

**Original titers calibrated to the WHO anti-SARS-CoV-2 immunoglobulin International Standard (NIBSC code: 20/136) for all data analyses.^{2,3} cID50 = calibrated ID50 titer; cID80 = calibrated ID80 titer.

Supplementary Text 2: Baseline covariates adjusted for in immune correlates analyses, including the baseline COVID-19 risk score

In addition to adjusting for the at-risk indicator (a stratification factor used in the COVE trial randomization) and the indicator of membership in community of color, all correlates analyses adjust for a baseline COVID-19 risk score that was developed through machine learning of the baseline SARS-CoV-2 negative per-protocol placebo arm data in the COVE trial. This supplementary text summarizes the COVID-19 risk score, with the Statistical Analysis Plan providing additional details.

Table S2 lists the input variables that were included in the machine learning to build a model predicting the COVID-19 endpoint, where cases are COVID-19 endpoints starting 7 days post Day 57 visit and noncases are participants with follow-up beyond 7 days post Day 57 visit and that never registered a COVID-19 endpoint. The risk score is defined as the logit of the predicted COVID-19 outcome probability from the predictive regression model, estimated using the ensemble algorithm superlearner (i.e. stacking), where this logit predicted outcome is scaled to have empirical mean zero and empirical standard deviation one.

Variable Name	Definition	Total missing values
MinorityInd	Baseline covariate underrepresented minority status	0/14079 (0.0%)
EthnicityHispanic	(1=minority, 0=non-minority)	0/14079 (0.0%)
	Indicator ethnicity = Hispanic (0 = Non-Hispanic)	
EthnicityNotreported	Indicator ethnicity = Not reported (0 = Non-Hispanic)	0/14079 (0.0%)
EthnicityUnknown	Indicator ethnicity = Unknown (0 = Non-Hispanic)	0/14079 (0.0%)
Black	Indicator race = Black $(0 = White)$	0/14079 (0.0%)
Asian	Indicator race = Asian $(0 = White)$	0/14079 (0.0%)
NatAmer	Indicator race = American Indian or Alaska Native (0	0/14079 (0.0%)
	=	
PacIsl	White)	0/14079 (0.0%)
	Indicator race = Native Hawaiian or Other Pacific	
Multiracial	Islander ($0 =$ White)	0/14079 (0.0%)
	Indicator race = Multiracial $(0 = White)$	
Other	Indicator race = Other $(0 = White)$	0/14079 (0.0%)
Notreported	Indicator race = Not reported $(0 = White)$	0/14079 (0.0%)
Unknown	Indicator race = unknown $(0 = White)$	0/14079 (0.0%)
HighRiskInd	Baseline covariate high risk pre-existing condition	0/14079 (0.0%)
Sex	(1=yes, 0=no)	0/14079 (0.0%)
	Sex assigned at birth (1=female, 0=male)	
Age	Age at enrollment in years, between 18 and 85	0/14079 (0.0%)
BMI	BMI at enrollment (kg/m^2)	79/14079 (0.6%)

Table S2. Individual baseline variables input into the Superlearner model for predicting occurrence of COVID-19 in baseline SARS-CoV-2 negative per-protocol placebo recipients.¹

¹The per-protocol group for immune correlates analysis is slightly different than that for the primary vaccine efficacy analysis,⁵ due in part to a data cutoff for the primary vaccine efficacy analysis of November 25, 2020⁵ vs a data cutoff for the immune correlates analysis of March 26, 2021, and also in part due to the inclusion of participants

with HIV in the per-protocol set for vaccine efficacy analysis⁵ vs. the exclusion of participants with HIV from the per-protocol set for the immune correlates analysis

The following details were used in the implementation of superlearner of the baseline SARS-CoV-2 negative per-protocol placebo arm:

- All of the selected learners (i.e., regression methods for classifying whether a participant has a COVID-19 outcome or not) were coded into the SuperLearner R package available on CRAN, and the analysis was done using this R package.
- Each quantitative and ordinal variable was pre-scaled to have empirical mean 0 and standard deviation 1.
- 5-fold cross-validation was used with no more than max(20,floor(np/20)) input variables included in each model, where np is the number of evaluable placebo arm cases.
- High-correlation variable screening was used, not allowing any pair of input variables to have Spearman rank correlation r > 0.9.
- Two levels of cross-validation (CV) were used. The outer level computed CV-AUC over 5-fold cross-validation, and the inner level used 5-fold CV.
- Results for comparing classification accuracy of different models were based on point and 95% confidence interval estimates of cross-validated area under the ROC curve (CV-AUC).^{6,7} Results are presented as forest plots of point and 95% confidence interval estimates similar to those used in Figure 3B of Neidich et al.⁸ and in Figure 2 of Magaret, Benkeser, and Williamson et al.⁹ CV-AUC was estimated using the *vimp* R package¹⁰ available on CRAN.

Table S3 lists the learning algorithms that were applied to estimate the conditional probability of the COVID-19 outcome based on the input variables listed in **Table S2**. Some of the algorithms are non-data-adaptive type learning algorithms, such as parametric regression models (e.g., generalized linear models [glms]), which are simple and stable. Data-adaptive type algorithms are also included, for increasing flexibility of modeling and reducing the risk of model misspecification: SL.randomForest, SL.gam, SL.polymars, and SL.xgboost. All of the selected learners are coded into the SuperLearner R package.

Learner	Screen*
SL.mean	all
SL.glm	all
	glmnet
	univar_logistic_pval
	highcor_random
SL.glm.interaction	glmnet
	univar_logistic_pval
	highcor_random
SL.glmnet	all
SL.gam	glmnet
	univar_logistic_pval
	highcor_random
SL.xgboost	all
SL.ranger.imp	all

 Table S3. Learning algorithm-screen combinations (14 in total) used as input to the Superlearner model in baseline negative per-protocol placebo recipients.

*Screen details:

all: includes all variables

glmnet: includes variables with non-zero coefficients in the standard implementation of SL.glmnet that optimizes the lasso tuning parameter via cross-validation

univar logistic pval: Wald test 2-sided p-value in a logistic regression model < 0.10

highcor_random: if pairs of quantitative variables with Spearman rank correlation > 0.90, select one of the variables at random

Table S4 shows the weights that the Superlearner ensemble model applied to each of the individual prediction algorithms in the modeling of the placebo arm.

Learner	Screen	Weight
SL.gam	screen_highcor_random	0.369
SL.gam	screen_univariate_logistic_pval	0.291
SL.ranger.imp	screen_all	0.165
SL.mean	screen_all	0.112
SL.xgboost	screen_all	0.062
SL.glm	screen_all	0.000
SL.glmnet	screen_all	0.000
SL.glm	screen_glmnet	0.000
SL.glm	screen_univariate_logistic_pval	0.000
SL.glm	screen_highcor_random	0.000
SL.glm.interaction	screen_glmnet	0.000
SL.glm.interaction	screen_univariate_logistic_pval	0.000
SL.glm.interaction	screen_highcor_random	0.000
SL.gam	screen_glmnet	0.000

Table S4. Weights assigned by Superlearner to each individual learner in the modeling of the placebo arm

To inform about which individual input variables were most important for the risk score, **Table S5** shows the predictors used in the learners that were assigned positive weight by the Superlearner model, with multiple metrics reported that can be used for ranking variable importance. BMI and age were ranked as the two most important variables for predicting COVID-19.

	Saucen	Watek	Duadiataur	Conffratori	Odds Datia	Income	Easterns	C	C	E
Learner	Screen screen highcor random	Weight 0.369	Predictors	Coefficient -3.109	Ratio 0.045	Importance NA	Feature NA	Gain NA	Cover NA	Frequenc NA
SL.gam	screen highcor random	0.369	(Intercept) s(Age,2)	-0.280	0.043	NA NA	NA	NA	NA	NA NA
SL.gam						NA		NA	NA	NA
SL.gam	screen_highcor_random	0.369	s(BMI,2)	0.174	1.190		NA			NA NA
SL.gam	screen_highcor_random	0.369	MinorityInd	-0.042	0.959	NA	NA	NA	NA	
SL.gam	screen_highcor_random	0.369	EthnicityHispanic	0.027	1.028	NA	NA	NA	NA	NA
SL.gam	screen_highcor_random	0.369	EthnicityNotreported	-0.046	0.955	NA	NA	NA	NA	NA
SL.gam	screen_highcor_random	0.369	EthnicityUnknown	-0.056	0.945	NA	NA	NA	NA	NA
SL.gam	screen_highcor_random	0.369	Black	-0.250	0.779	NA	NA	NA	NA	NA
SL.gam	screen_highcor_random	0.369	Asian	-0.047	0.954	NA	NA	NA	NA	NA
SL.gam	screen_highcor_random	0.369	NatAmer	-0.059	0.943	NA	NA	NA	NA	NA
SL.gam	screen_highcor_random	0.369	PacIsl	-0.442	0.643	NA	NA	NA	NA	NA
SL.gam	screen_highcor_random	0.369	Multiracial	-0.143	0.866	NA	NA	NA	NA	NA
SL.gam	screen_highcor_random	0.369	Other	0.018	1.018	NA	NA	NA	NA	NA
SL.gam	screen_highcor_random	0.369	Notreported	0.033	1.034	NA	NA	NA	NA	NA
SL.gam	screen_highcor_random	0.369	Unknown	0.029	1.030	NA	NA	NA	NA	NA
SL.gam	screen_highcor_random	0.369	HighRiskInd	0.007	1.007	NA	NA	NA	NA	NA
SL.gam	screen_highcor_random	0.369	Sex	0.054	1.056	NA	NA	NA	NA	NA
SL.gam	screen_univariate_logistic_pval	0.291	(Intercept)	-3.084	0.046	NA	NA	NA	NA	NA
SL.gam	screen_univariate_logistic_pval	0.291	s(Age,2)	-0.274	0.761	NA	NA	NA	NA	NA
SL.gam	screen_univariate_logistic_pval	0.291	s(BMI,2)	0.183	1.201	NA	NA	NA	NA	NA
SL.gam	screen_univariate_logistic_pval	0.291	EthnicityHispanic	0.010	1.010	NA	NA	NA	NA	NA
SL.gam	screen_univariate_logistic_pval	0.291	Black	-0.268	0.765	NA	NA	NA	NA	NA
SL.gam	screen univariate logistic pval	0.291	Multiracial	-0.150	0.861	NA	NA	NA	NA	NA
SL.ranger.imp	screen all	0.165	MinorityInd	NA	NA	3.296	NA	NA	NA	NA
SL.ranger.imp	screen all	0.165	EthnicityHispanic	NA	NA	3.844	NA	NA	NA	NA
SL.ranger.imp	screen_all	0.165	EthnicityNotreported	NA	NA	1.069	NA	NA	NA	NA
SL.ranger.imp	screen all	0.165	EthnicityUnknown	NA	NA	0.433	NA	NA	NA	NA
SL.ranger.imp	screen all	0.165	Black	NA	NA	2.608	NA	NA	NA	NA
SL.ranger.imp	screen all	0.165	Asian	NA	NA	2.318	NA	NA	NA	NA
SL.ranger.imp	screen all	0.165	NatAmer	NA	NA	0.971	NA	NA	NA	NA
SL.ranger.imp	screen_all	0.165	PacIsl	NA	NA	0.133	NA	NA	NA	NA
SL.ranger.imp	screen_all	0.165	Multiracial	NA	NA	1.394	NA	NA	NA	NA
SL.ranger.imp	screen_all	0.165	Other	NA	NA	2.155	NA	NA	NA	NA

Table S5. Predictors in learners assigned positive weight by Superlearner in the modeling of the placebo arm.

SL.ranger.imp	screen_all	0.165	Notreported	NA	NA	1.390	NA	NA	NA	NA
SL.ranger.imp	screen_all	0.165	Unknown	NA	NA	1.682	NA	NA	NA	NA
SL.ranger.imp	screen_all	0.165	HighRiskInd	NA	NA	4.380	NA	NA	NA	NA
SL.ranger.imp	screen_all	0.165	Sex	NA	NA	6.329	NA	NA	NA	NA
SL.ranger.imp	screen_all	0.165	Age	NA	NA	50.511	NA	NA	NA	NA
SL.ranger.imp	screen_all	0.165	BMI	NA	NA	109.263	NA	NA	NA	NA
SL.xgboost	screen_all	0.062	NA	NA	NA	NA	BMI	0.664	0.796	0.75
SL.xgboost	screen_all	0.062	NA	NA	NA	NA	Age	0.238	0.153	0.17
SL.xgboost	screen_all	0.062	NA	NA	NA	NA	Sex	0.025	0.006	0.01
SL.xgboost	screen_all	0.062	NA	NA	NA	NA	Black	0.022	0.018	0.01
SL.xgboost	screen_all	0.062	NA	NA	NA	NA	MinorityInd	0.018	0.009	0.01
SL.xgboost	screen_all	0.062	NA	NA	NA	NA	HighRiskInd	0.014	0.006	0.01
SL.xgboost	screen_all	0.062	NA	NA	NA	NA	EthnicityHispanic	0.011	0.004	0.00
SL.xgboost	screen_all	0.062	NA	NA	NA	NA	Multiracial	0.007	0.004	0.00
SL.xgboost	screen_all	0.062	NA	NA	NA	NA	Asian	0.001	0.003	0.00
SL.xgboost	screen_all	0.062	NA	NA	NA	NA	Other	0.000	0.001	0.00

Figure S3 Panel A shows the cross-validated receiver operating characteristic curve for the 2 topperforming learners, Superlearner, and the Discrete Superlearner models classifying COVID-19 outcome status in baseline SARS-CoV-2 negative per-protocol placebo recipients, with predictive performance summarized by cross-validated area under the receiver operating characteristic curve (CV-AUC). The point estimate of CV-AUC for the Superlearner was 0.612 with 95% CI 0.591, 0.633.

Figure S3 Panel B shows the receiver operating characteristic curve for the Superlearner model built from baseline SARS-CoV-2 negative per-protocol placebo recipients applied to baseline SARS-CoV-2 negative per-protocol vaccine recipients, for which the point estimate of AUC for classifying COVID-19 outcome status was 0.614.

Figure S3. (A) Cross-validated receiver operating characteristic curve for the 2 top-performing learners, Superlearner, and the Discrete Superlearner models classifying COVID-19 outcome occurrence in baseline SARS-CoV-2 negative per-protocol placebo recipients, with cross-validated area under the curve (CV-AUC) summarizing classification performance. (B) Receiver operating characteristic curve for the Superlearner upon applying the model built from placebo recipients to baseline SARS-CoV-2 negative per-protocol vaccine recipients, with AUC in parentheses summarizing classification performance.




Figure S4 shows Superlearner model predicted probabilities of the COVID-19 endpoint starting 7 days post Day 57 visit by case vs. non-case status, for baseline SARS-CoV-2 negative per-protocol vaccine recipients in the case-cohort set.

Figure S4. Superlearner model predicted probabilities of the COVID-19 endpoint starting 7 days post Day 57 visit by case vs. non-case (i.e., control) status, for baseline SARS-CoV-2 negative per-protocol vaccine recipients in the case-cohort set.




Table S6. Numbers of participants in the case-cohort set by baseline sampling strata. Case-cohort set = baseline SARS-CoV-2 negative per-protocol participants sampled into the immunogenicity subcohort or acquired the COVID-19 primary endpoint: all such participants have Day 1, 29, 57 antibody data, except for Day 29 marker correlates analyses intercurrent cases may not have Day 57 antibody data and Day 57 antibody data are not used.

	Baselin	Baseline Sampling Strata of SARS-CoV-2 Negative Participants							
	1	2	3	4	5	6	Total		
Vaccine									
Day 29 Cases	1	6	2	8	9	20	46		
Day 57 Cases	1	4	2	8	5	16	36		
Non-Cases	171	168	143	146	188	189	1005		
Placebo									
Day 29 Cases	9	63	35	69	99	267	542		
Day 57 Cases	8	51	24	61	70	227	441		
Non-Cases	22	23	20	18	24	26	133		

Demographic covariate strata:

- 1. Age \geq 65 Minority
- 2. Age \geq 65 Non-Minority
- 3. Age < 65 At-risk Minority
- 4. Age < 65 At-risk Non-Minority
- 5. Age < 65 Not At-risk Minority
- 6. Age < 65 Not At-risk Non-Minority

Minority includes Blacks or African Americans, Hispanics or Latinos, American Indians or Alaska Natives, Native Hawaiians, and other Pacific Islanders.

Non-Minority includes all other races with observed race (Asian, Multiracial, White, Other) and observed ethnicity Not Hispanic or Latino.

Unknown includes unknown, unreported race or ethnicity.

Cases for Day 29 marker correlates analyses are baseline SARS-CoV-2 negative per-protocol vaccine recipients with the symptomatic infection COVID-19 primary endpoint diagnosed starting 7 days after the Day 29 study visit. Cases for Day 57 marker correlates analyses are baseline SARS-CoV-2 negative per-protocol vaccine recipients with the symptomatic infection COVID-19 primary endpoint diagnosed starting 7 days after the Day 57 study visit. Non-cases are baseline SARS-CoV-2 negative per-protocol participants sampled into the immunogenicity subcohort with no COVID-19 primary endpoint up to the time of data cut and no evidence of SARS-CoV-2 infection up to six days post Day 57 visit.

Characteristics	Vaccine (N = 1010)	Placebo $(N = 137)$	Total (N = 1147)
Age			
Age < 65	670 (66.3%)	91 (66.4%)	761 (66.3%)
$Age \ge 65$	340 (33.7%)	46 (33.6%)	386 (33.7%)
$Age \ge 0.5$ Mean (Range)	54.6 (18.0, 87.0)	53.4 (19.0, 85.0)	54.4 (18.0, 87.0)
BMI	54.0 (10.0, 07.0)	55.4 (17.0, 65.0)	54.4 (10.0, 07.0)
Mean ± SD	30.9 ± 7.6	31.3±9.0	30.9 ± 7.8
Risk for Severe COVID-19	50.9 - 7.0	51.52 7.0	50.74 1.0
	20((20, 20/))	57 (41 (0/)	452 (20 50/)
At-risk	396 (39.2%)	57 (41.6%)	453 (39.5%)
Not at-risk	614 (60.8%)	80 (58.4%)	694 (60.5%)
Age, Risk for Severe COVID-19			
Age < 65 At-risk	291 (28.8%)	40 (29.2%)	331 (28.9%)
Age < 65 Not at-risk	379 (37.5%)	51 (37.2%)	430 (37.5%)
$Age \ge 65$	340 (33.7%)	46 (33.6%)	386 (33.7%)
Sex Assigned at Birth			
Female	476 (47.1%)	63 (46.0%)	539 (47.0%)
Male	534 (52.9%)	74 (54.0%)	608 (53.0%)
Hispanic or Latino Ethnicity			
Hispanic or Latino	322 (31.9%)	44 (32.1%)	366 (31.9%)
Not Hispanic or Latino	685 (67.8%)	93 (67.9%)	778 (67.8%)
Not reported and unknown	3 (0.3%)	0 (0.0%)	3 (0.3%)
Race		. /	. /
White	735 (72.8%)	99 (72.3%)	834 (72.7%)
Black or African American	182 (18.0%)	24 (17.5%)	206 (18.0%)
Asian	25 (2.5%)	6 (4.4%)	31 (2.7%)
American Indian or Alaska Native	17 (1.7%)	2 (1.5%)	19 (1.7%)
Native Hawaiian or Other Pacific Islander	5 (0.5%)	0 (0.0%)	5 (0.4%)
Multiracial	12 (1.2%)	4 (2.9%)	16 (1.4%)
Other	25 (2.5%)	2 (1.5%)	27 (2.4%)
Not reported and unknown	9 (0.9%)	0 (0.0%)	9 (0.8%)
White Non-Hispanic	468 (46.3%)	61 (44.5%)	529 (46.1%)
Communities of Color	542 (53.7%)	76 (55.5%)	618 (53.9%)

Table S7. Demographics and clinical characteristics of baseline SARS-CoV-2 negative per-protocol trial participants in the immunogenicity subcohort and thus have Day 1, 29, 57 antibody marker data.

This table summarizes the baseline SARS-CoV-2 negative per-protocol immunogenicity subcohort, which was randomly sampled within 12 strata defined by enrollment characteristics: Assigned treatment arm × Baseline SARS-CoV-2 naïve vs. non-naïve status (defined by serostatus and NAAT testing) × Randomization strata (Age < 65 and at-risk, Age < 65 and not at-risk, Age \geq 65)× Community of color (Yes/No) defined by White Non-Hispanic vs. all others (same as in Baden et al.⁵).

Figure S5. For each antibody marker, correlations of Day 29 levels with Day 57 levels in baseline SARS-CoV-2 negative per-protocol vaccine recipients in the immunogenicity subcohort. Corr = baseline variable adjusted Spearman rank correlation.




Figure S6. Correlations of Day 29 antibody markers in baseline SARS-CoV-2 negative per-protocol vaccine recipients in the immunogenicity subcohort. cID50, cID80: calibrated ID50, ID80 titer. Corr = baseline variable adjusted Spearman rank correlation.




Figure S7. Correlations of Day 57 antibody markers in baseline SARS-CoV-2 negative per-protocol vaccine recipients in the immunogenicity subcohort. cID50, cID80: calibrated ID50, ID80 titer. Corr = baseline variable adjusted Spearman rank correlation.






Figure S8. A) Anti-RBD IgG concentration and B) pseudovirus neutralization cID80 titer by COVID-19 outcome status. Data points are from baseline SARS-CoV-2 negative per-protocol vaccine recipients selected into the case-cohort set. Pos.Cut, Positivity cut-off. LoD, limit of detection. ULoQ, upper limit of quantitation; ULOQ = 15,368 for cID80 (above all data points). Post Day 57 cases are COVID endpoints starting 7 days post Day 57 visit; Intercurrent cases are COVID endpoints starting 7 days post Day 29 visit through 6 days post Day 57 visit.




Category 💿 Intercurrent Cases 🕒 Post Day 57 Cases 💿 Non-Cases



Category 🖸 Intercurrent Cases 🔺 Post Day 57 Cases 💿 Non-Cases

Figure S9. Marker values (Spike IgG, RBD IgG, cID50, cID80) by COVID-19 outcome status in placebo recipients. Data points are from baseline SARS-CoV-2 negative per-protocol placebo recipients selected into the case-cohort set. Positive response rates are computed with Inverse Probability Sampling (IPS) weighting. Pos.Cut, Positivity cut-off. LoD, limit of detection. ULoQ, upper limit of quantitation.



Category Intercurrent Cases Post Day 57 Cases Non-Cases

Category 💽 Intercurrent Cases 🔺 Post Day 57 Cases 💿 Non-Cases

Figure S10. Day 29 marker data points from baseline SARS-CoV-2 negative per-protocol vaccine recipients selected into the case-cohort set. Non-cases are represented by orange dots, intercurrent cases by large blue circles, and post Day 57 cases by large purple squares.




Figure S11. Day 57 marker data points from baseline SARS-CoV-2 negative per-protocol vaccine recipients selected into the case-cohort set. Non-cases are represented by orange dots, intercurrent cases by large blue circles, and post Day 57 cases by large purple squares.




Figure S12. Inverse probability sampling (IPS)-weighted empirical reverse cumulative distribution function curves for each Day 57 marker (Spike IgG, RBD IgG, cID50, cID80) and application of the Siber (2007) method¹¹ for estimating a threshold of perfect vs. no protection. cID50, cID80: calibrated ID50, ID80 titer.




Figure S13. Inverse probability sampling (IPS)-weighted empirical reverse cumulative distribution function curves for each Day 29 marker (Spike IgG, RBD IgG, cID50, cID80) and application of the Siber (2007) method¹¹ for estimating a threshold of perfect vs. no protection. cID50, cID80: calibrated ID50, ID80 titer.




Figure S14. Day 29 and Day 57 antibody markers (Spike IgG, RBD IgG, cID50, cID80) vs. number of days from Day 29 visit until COVID-19 primary endpoint diagnosis for per-protocol baseline SARS-CoV-2 negative vaccine recipient breakthrough cases. Blue circles are Day 29 marker values for Intercurrent Cases. Orange triangles are Day 29, Day 57 marker values for Post Day 57 cases, with paired marker values from the same participant joined by a vertical line segment, with Day 57 marker value always the top triangle. cID50, cID80: calibrated ID50, ID80 titer.






Figure S15: Covariate-adjusted cumulative incidence of COVID-19 by Low, Medium, High tertile of Day 57 IgG concentration or pseudovirus neutralization titer. (A) Anti-RBD IgG concentration; (B) cID80 titer.



*No. At-Risk = estimated number in the population for analysis: baseline negative per-protocol vaccine recipients not experiencing the COVID-19 endpoint through 6 days post Day 57 visit. **Cumulative No. of COVID-19 Endpoints = estimated cumulative number of this cohort with a COVID-19 endpoint.

Figure S16. Covariate-adjusted cumulative incidence of COVID-19 by Low, Medium, High tertile of Day 29 IgG concentration or pseudovirus neutralization titer. (A) Anti-Spike IgG concentration; (B) cID50 titer; (C) IgG (Spike, RBD) and (cID50, cID80). The overall p-value is from a generalized Wald test for whether the COVID-19 hazard differed across Low, Medium, and High subgroups.



*No. At-Risk = estimated number in the population for analysis; baseline negative per-protocol vaccine recipients not experiencing the COVID-19 endpoint through 6 days post Day 29 visit.
**Cumulative No. of COVID-19 Endpoints = estimated cumulative number of this cohort with a COVID-19 endpoint

С

COVE	Tertile [¶]	No. cases /	Attack	Haz	. Ratio	P-value	Overall P-	Overall q-	Overall
Immunologic Marker		No. at-risk [§]	rate	Pt. Est.	95% CI	(2-sided)	value	$value^{\dagger}$	FWER
Anti Spike IgG (IU/ml)	Low	33/4,509	0.0073	1	N/A	N/A	< 0.001	< 0.001	< 0.001
	Medium	13/4,897	0.0027	0.31	(0.15, 0.65)	0.002			
	High	8/4,735	0.0017	0.19	(0.08, 0.44)	< 0.001			
Anti RBD IgG (IU/ml)	Low	30/4,559	0.0066	1	N/A	N/A	0.002	0.004	0.003
	Medium	14/4,803	0.0029	0.40	(0.19, 0.84)	0.016			
	High	11/4,779	0.0023	0.28	(0.13, 0.60)	0.001			
Pseudovirus-nAb cID50	Low	33/4,688	0.0070	1	N/A	N/A	< 0.001	0.001	0.001
	Medium	8/4,778	0.0017	0.22	(0.09, 0.53)	< 0.001			
	High	13/4,675	0.0028	0.32	(0.15, 0.69)	0.003			
Pseudovirus-nAb cID80	Low	31/4,709	0.0066	1	N/A	N/A	0.001	0.003	0.002
	Medium	16/4,827	0.0033	0.44	(0.21, 0.90)	0.025			
	High	$8/4,\!604$	0.0017	0.22	(0.09, 0.51)	$<\!0.001$			
Placebo		734/13,972	0.0525						

Baseline covariates adjusted for: baseline risk score, at risk or not, community of color or not.

Maximum failure event time 126 days post Day 29 visit.

¹Tertiles:

Spike IgG: Low is < 234 IU/ml, Medium is 234 to 513 IU/ml, High is > 513 IU/ml.

RBD IgG: Low is < 234 IU/ml, Medium is 234 to 537 IU/ml, High is > 537 IU/ml.


ID50: Low is < 8.3, Medium is 8.3 to 23, High is > 23 (all in calibrated titer).

ID80: Low is < 21, Medium is 21 to 40, High is > 40 (all in calibrated titer).

^{\$}No. at-risk = estimated number in the population for analysis: baseline negative per-protocol vaccine recipients not experiencing the</sup>COVID-19 endpoint through 6 days post Day 29 visit; No. cases = estimated number of this cohort with an observed COVID-19 endpoint.

† q-value and FWER (family-wide error rate) are computed over the set of p-values both for quantitative markers and categorical markers using the Westfall and Young permutation method (10000 replicates).

Figure S17: Covariate-adjusted cumulative incidence of COVID-19 by Low, Medium, High tertile of Day 29 IgG concentration or pseudovirus neutralization titer. (A) Anti-RBD IgG concentration; (B) cID80 titer.



*No. At-Risk = estimated number in the population for analysis: baseline negative per-protocol vaccine recipients not experiencing the COVID-19 endpoint through 6 days post Day 29 visit. **Cumulative No. of COVID-19 Endpoints = estimated cumulative number of this cohort with a COVID-19 endpoint. Figure S18. Covariate-adjusted hazard ratios of COVID-19 per 10-fold increase in each Day 29 antibody marker in baseline SARS-CoV-2 negative per-protocol vaccine recipients overall and in subgroups. (A) Inferences for IgG (Spike, RBD) and (cID50, cID80); (B) Forest plots for anti-Spike IgG concentration; (C) Forest plots for cID50.

	۸
'	٦

COVE	No. cases /	HR per 1	10-fold incr.	P-value	q-value	FWER
Immunologic Marker	No. at-risk $*$	Pt. Est.	95% CI	(2-sided)	**	
Anti Spike IgG (IU/ml)	55/14,141	0.54	(0.40, 0.74)	< 0.001	< 0.001	< 0.001
Anti RBD IgG (IU/ml)	55/14,141	0.46	(0.30, 0.70)	$<\!0.001$	0.001	0.001
Pseudovirus-nAb cID50	55/14,141	0.33	(0.17, 0.65)	0.001	0.003	0.002
Pseudovirus-nAb cID80	55/14,141	0.19	(0.07, 0.56)	0.003	0.004	0.003

*No. at-risk = estimated number in the population for analysis: baseline negative per-protocol vaccine recipients not experiencing the COVID-19 endpoint through 6 days post Day 29 visit; No. cases = estimated number of this cohort with an observed COVID-19 endpoint starting 7 days post Day 29 visit.

** q-value and FWER (family-wide error rate) are computed over the set of p-values both for quantitative markers and categorical markers using the Westfall and Young permutation method (10000 replicates).

В	Binding Antibody to Spike: Day 29						
Group	No. Events		HR (95% CI)				
All Vaccine	55	-	0.54 (0.40, 0.74)				
Age ≥ 65	9		0.53 (0.33, 0.85)				
Age < 65	46		0.53 (0.36, 0.79)				
At risk	16		0.65 (0.38, 1.13)				
Not at risk	39	-	0.51 (0.35, 0.75)				
Comm. of color	16	_	0.34 (0.16, 0.72)				
White Non-Hispanic	39		0.60 (0.44, 0.82)				
Male	25		0.72 (0.49, 1.08)				
Female	30	-	0.42 (0.24, 0.73)				
			7				
	0	0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8	2				

С	Ps	/ Neutralization 50% Titer: Day 29	
Group	No. Events		HR (95% CI)
All Vaccine	55		0.33 (0.17, 0.65)
Age ≥ 65	9		0.29 (0.06, 1.33)
Age < 65	46	_	0.33 (0.16, 0.69)
At risk	16		→ 0.90 (0.37, 2.18)
Not at risk	39		0.20 (0.09, 0.43)
Comm. of color	16		0.35 (0.09, 1.41)
White Non-Hispanic	39	-	0.31 (0.15, 0.64)
Male	25		0.45 (0.17, 1.21)
Female	30		0.26 (0.11, 0.62)
		0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6	1.8 2

Figure S19. Covariate-adjusted risk of COVID-19 by the level of each Day 57 marker (Spike IgG, RBD IgG, cID50, cID80), estimated with a generalized additive model.




Figure S20. Covariate-adjusted risk of COVID-19 by the level of each Day 29 marker (Spike IgG, RBD IgG, cID50, cID80), estimated with a generalized additive model.






Figure S21. (A) Covariate-adjusted risk of COVID-19 by subgroups defined by Day 57 cID80 level above a threshold, with reverse cumulative distribution function of Day 57 cID80 level overlaid in green; (B) Covariate-adjusted cumulative incidence of COVID-19 by 100 days post Day 57 by Day 57 cID80 level; (C) Vaccine efficacy by Day 57 cID80 level. In (A), the gray shaded area is pointwise 95% confidence intervals (CIs). The upper boundary of the green shaded area is the estimate of the reverse cumulative distribution function of the marker in baseline SARS-CoV-2 negative per-protocol vaccine recipients. In (B), the dotted lines indicate bootstrap point-wise 95% CIs. In (C), vaccine efficacy estimates were obtained using the method of Gilbert, Fong, and Carone.¹² In (B) and (C), the green histograms are an estimate of the density of marker level in baseline negative per-protocol vaccine recipients. LOD, limit of detection. cID80: ID80 nAb titer calibrated to the WHO International Standard.





PsV Neutralization 80% Titer: Day 57

Pseudovirus-nAb clD80 (=s)





Figure S22. (A) Covariate-adjusted risk of COVID-19 by subgroups defined by Day 57 Anti-Spike IgG level above a threshold, with reverse cumulative distribution function of Day 57 Anti-Spike IgG level overlaid in green; (B) Covariate-adjusted cumulative incidence of COVID-19 by 100 days post Day 57 by Day 57 Anti-Spike IgG level; (C) Controlled vaccine efficacy by Day 57 Anti-Spike IgG level. In (A), the gray shaded area is pointwise 95% confidence intervals (CIs). The upper boundary of the green shaded area is the estimate of the reverse cumulative distribution function of the marker in baseline SARS-CoV-2 negative per-protocol vaccine recipients. In (B), the dotted lines indicate bootstrap point-wise 95% CIs. In (C), vaccine efficacy estimates were obtained using the method of Gilbert, Fong, and Carone.¹² In (B) and (C), the green histograms are an estimate of the density of marker level in baseline negative per-protocol vaccine recipients. LOD, limit of detection.







Figure S23. (A) Covariate-adjusted risk of COVID-19 by subgroups defined by Day 57 Anti-RBD IgG level above a threshold, with reverse cumulative distribution function of Day 57 Anti-RBD IgG level overlaid in green; (B) Covariate-adjusted cumulative incidence of COVID-19 by 100 days post Day 57 by Day 57 Anti-RBD IgG level; (C) Controlled vaccine efficacy by Day 57 Anti-RBD IgG level. In (A), the gray shaded area is pointwise 95% confidence intervals (CIs). The upper boundary of the green shaded area is the estimate of the reverse cumulative distribution function of the marker in baseline SARS-CoV-2 negative per-protocol vaccine recipients. In (B), the dotted lines indicate bootstrap point-wise 95% CIs. In (C), vaccine efficacy estimates were obtained using the method of Gilbert, Fong, and Carone.¹² In (B) and (C), the green histograms are an estimate of the density of marker level in baseline negative per-protocol vaccine recipients. LOD, limit of detection.










Figure S24. (A) Covariate-adjusted risk of COVID-19 by subgroups defined by Day 29 cID50 level above a threshold, with reverse cumulative distribution function of Day 29 cID50 level overlaid in green; (B) Covariate-adjusted cumulative incidence of COVID-19 by 126 days post Day 29 by Day 29 cID50 level; (C) Controlled vaccine efficacy by Day 29 cID50 level. In (A), the gray shaded area is pointwise 95% confidence intervals (CIs). The upper boundary of the green shaded area is the estimate of the reverse cumulative distribution function of the marker in baseline SARS-CoV-2 negative per-protocol vaccine recipients. In (B), the dotted lines indicate bootstrap point-wise 95% CIs. In (C), vaccine efficacy estimates were obtained using the method of Gilbert, Fong, and Carone.¹² In (B) and (C), the green histograms are an estimate of the density of marker level in baseline negative per-protocol vaccine recipients. LOD, limit of detection. cID50: ID50 nAb titer calibrated to the WHO International Standard.




Pseudovirus-nAb cID50 (=s)



Pseudovirus-nAb cID50 (=s)

Figure S25. (A) Covariate-adjusted risk of COVID-19 by subgroups defined by Day 29 cID80 level above a threshold, with reverse cumulative distribution function of Day 29 cID80 level overlaid in green; (B) Covariate-adjusted cumulative incidence of COVID-19 by 126 days post Day 29 by Day 29 cID80 level; (C) Controlled vaccine efficacy by Day 29 cID80 level. In (A), the gray shaded area is pointwise 95% confidence intervals (CIs). The upper boundary of the green shaded area is the estimate of the reverse cumulative distribution function of the marker in baseline SARS-CoV-2 negative per-protocol vaccine recipients. In (B), the dotted lines indicate bootstrap point-wise 95% CIs. In (C), vaccine efficacy estimates were obtained using the method of Gilbert, Fong, and Carone.¹² In (B) and (C), the green histograms are an estimate of the density of marker level in baseline negative per-protocol vaccine recipients. LOD, limit of detection. cID80: ID80 nAb titer calibrated to the WHO International Standard.









Figure S26. (A) Covariate-adjusted risk of COVID-19 by subgroups defined by Day 29 Anti-Spike IgG level above a threshold, with reverse cumulative distribution function of Day 29 Anti-Spike IgG level overlaid in green; (B) Covariate-adjusted cumulative incidence of COVID-19 by 126 days post Day 29 by Day 29 Anti-Spike IgG level; (C) Controlled vaccine efficacy by Day 29 Anti-Spike IgG level. In (A), the gray shaded area is pointwise 95% confidence intervals (CIs). The upper boundary of the green shaded area is the estimate of the reverse cumulative distribution function of the marker in baseline SARS-CoV-2 negative per-protocol vaccine recipients. In (B), the dotted lines indicate bootstrap point-wise 95% CIs. In (C), vaccine efficacy estimates were obtained using the method of Gilbert, Fong, and Carone.¹² In (B) and (C), the green histograms are an estimate of the density of marker level in baseline negative per-protocol vaccine recipients. LOD, limit of detection.






58

Figure S27. (A) Covariate-adjusted risk of COVID-19 by subgroups defined by Day 29 Anti-RBD IgG level above a threshold, with reverse cumulative distribution function of Day 29 Anti-RBD IgG level overlaid in green; (B) Covariate-adjusted cumulative incidence of COVID-19 by 126 days post Day 29 by Day 29 Anti-RBD IgG level; (C) Controlled vaccine efficacy by Day 29 Anti-RBD IgG level. In (A), the gray shaded area is pointwise 95% confidence intervals (CIs). The upper boundary of the green shaded area is the estimate of the reverse cumulative distribution function of the marker in baseline SARS-CoV-2 negative per-protocol vaccine recipients. In (B), the dotted lines indicate bootstrap point-wise 95% CIs. In (C), vaccine efficacy estimates were obtained using the method of Gilbert, Fong, and Carone.¹² In (B) and (C), the green histograms are an estimate of the density of marker level in baseline negative per-protocol vaccine recipients. LOD, limit of detection.





Supplementary Text 3: Controlled vaccine efficacy sensitivity analysis to assess robustness of the effect of antibody marker on preventing COVID-19 to unmeasured confounding

Figure 2 reports results for estimation and inference for baseline covariate-marginalized COVID-19 risk ratios comparing vaccine recipients with Day 57 antibody marker in the third tertile vs. in the first tertile; denote this marginalized risk ratio by $RR_{M}(0,1)$, where 1 indicates the third tertile and 0 indicates the first tertile. As described in the SAP and Gilbert, Fong, and Carone,¹² under the assumption of no unmeasured confounding of the effect of the antibody marker on COVID-19, the COVID-19 risk ratio $RR_{M}(0,1)$ equals a causal effect parameter $RR_{C}(0,1)$, the controlled effects risk ratio, which in turn equals (1 -CVE(1))/(1 - CVE(0)), where CVE(1) is controlled vaccine efficacy for vaccine recipients with third tertile marker level and CVE(0) is controlled vaccine efficacy for vaccine recipients with first tertile marker level. In sensitivity analysis, we allow for some unmeasured confounding that makes $RR_M(0,1) < 0$ $RR_{C}(0,1)$. In particular, as specified in the SAP the first part of the sensitivity analysis reports E-values, both for the point estimate of $RR_{C}(0,1)$ and for the upper 95% confidence limit of $RR_{C}(0,1)$. The E-value is the minimum strength of association, on the risk ratio scale, that an unmeasured confounder would need to have with both the antibody marker (exposure) and the COVID-19 outcome in order to fully explain away a specific observed exposure-outcome association, conditional on the measured covariates.¹³ Here 'fully explain away' means that $RR_{C}(0,1) = 1$, or equivalently CVE(0) = CVE(1), i.e., controlled vaccine efficacy does not differ by upper vs. lower tertile, which means no correlate of protection. Many epidemiologists recommend that E-values are always reported (or alternative sensitivity metrics) for causal inferences, given that it is not possible to guarantee that all confounders are controlled for in the analysis; thus by using E-values we are implementing best practice.

In addition, we apply the sensitivity analysis technique developed by Ding and Vanderweele (2016),¹⁴ as implemented in the SAP and in Gilbert, Fong, and Carone¹² for the COVE trial correlates application, to estimate $RR_C(0,1) = (1 - CVE(1))/(1 - CVE(0))$ under a specified scenario of unmeasured confounding that makes it harder to conclude a correlate of protection. This sensitivity analysis specifies an amount of unmeasured confounding defined by $RR_{UD}(0,1)=RR_{EU}(0,1)=2$, where these parameters are defined in Ding and Vanderweele (2016)¹⁴ and in our SAP and Gilbert et al. If the 95% confidence interval for $RR_C(0,1) = (1 - CVE(1))/(1 - CVE(0))$ is less than 1 after accounting for this confounding that pushes the confidence interval upwards, it provides evidence for a correlate of protection with a degree of robustness to possible unmeasured confounding.

Table S8 shows results for the eight Day 57 and Day 29 antibody markers categorized by upper vs. lower tertile that were assessed as correlates. For example, the E-value of 9.3 for the Day 57 cID80 marker means that a marginalized risk ratio $RR_M(0,1)$ at the observed value 0.20 could be explained away (i.e., $RR_C(0,1) = 1.0$) by an unmeasured confounder associated with both the exposure and the outcome by a marginalized risk ratio of 9.3-fold each, after accounting for the measured potential confounders (risk score, at-risk status, community of color indicator), but that weaker confounding could not do so. In addition, the E-value of 3.3 for the upper confidence limit UL indicates the strength of unmeasured confounding at which statistical significance of the inference that CVE(1) > CVE(0) would be lost.

	Marginalized Risk Ratio RR _M (0,1)		Controlled Risk Ratio = $(1-CVE(1))/(1-CVE(0))^1$		E-values ²	
Antibody Marker	Point Est.	95% CI	Point Est.	95% CI	For Point Est.	For 95% CI UL
Day 57 Spike IgG	0.24	0.06, 0.56	0.32	0.09, 0.75	7.9	3.0
Day 57 RBD IgG	0.28	0.08, 0.62	0.38	0.11, 0.83	6.5	2.6
Day 57 PsV cID50	0.31	0.08, 0.72	0.42	0.11, 0.96	5.9	2.1
Day 57 PsV cID80	0.20	0.03, 0.51	0.27	0.05, 0.68	9.3	3.3
Day 29 Spike IgG	0.19	0.06, 0.40	0.26	0.08, 0.53	9.8	4.5
Day 29 RBD IgG	0.29	0.10, 0.59	0.38	0.13, 0.79	6.5	2.8
Day 29 PsV cID50	0.33	0.13, 0.65	0.44	0.17, 0.86	5.5	2.5
Day 29 PsV cID80	0.22	0.07, 0.46	0.30	0.10, 0.61	8.5	3.8

Table S8. Sensitivity analysis to assess Day 57 and Day 29 antibody markers categorized as upper vs. lower tertiles as controlled vaccine efficacy CoPs against COVID-19

¹Conservative (upper bound) estimate assuming unmeasured confounding at level RRUD(0, 1) =

RREU(0, 1) = 2 and thus B(0, 1) = 4/3.

²E-values are computed for upper tertile (s = 1) vs. lower tertile (s = 0) biomarker subgroups after controlling for baseline risk score, at risk or not, community of color or not; UL = upper limit.


A second sensitivity analysis was conducted to assess robustness of findings on correlates of vaccine efficacy as a function of the quantitative antibody marker level varying over its whole range as studied in **Figure 4C** for cID50 titer and in **Figures S21-S27** for the other seven antibody markers. With details in the SAP and Gilbert, Fong, and Carone,¹² the sensitivity analysis was done similar to the analysis above for categorized markers, except now instead of specifying $RR_{UD}(0,1)$ and $RR_{EU}(0,1)$ for third tertile vs. first tertile, we specified $RR_{UD}(s^{15}, s^{85}) = 2$ and $RR_{EU}(s^{15}, s^{85}) = 2$ for s¹⁵ the 15th percentile of the antibody marker and s⁸⁵ the 85th percentile of the antibody marker. We then specified unmeasured confounding across the whole range of antibody marker levels through the model


 $log(RR_{UD}(s1, s2)) = [(s2 - s1)/(s^{85} - s^{15})] log(RR_{UD}(s^{15}, s^{85}))$ for all $s1 \le s2$,

with the same model used for $RR_{EU}(s1, s2)$. The result of the sensitivity analysis is point estimates of controlled vaccine efficacy CVE(s) over the range s of antibody marker levels, with 95% bootstrap pointwise confidence intervals, which build in robustness to unmeasured confounding by supposing bias that makes the estimate of the curve CVE(s) flatter.

Figures S28 and S29 show the results for the eight antibody markers.

Figure S28. Vaccine efficacy with sensitivity analysis by Day 57 (A) Anti-Spike IgG level, (B) Anti-RBD IgG level, (C) cID50 level, or (D) cID80 level. Vaccine efficacy estimates were obtained using the method of Gilbert, Fong, and Carone.¹² The upper boundary of the green shaded area is the estimate of the reverse cumulative distribution function of the marker in baseline SARS-CoV-2 negative per-protocol vaccine recipients. The pink solid line is point estimates assuming no unmeasured confounding; the dashed lines are bootstrap point-wise 95% CIs. The red solid line is point estimates assuming unmeasured confounding in a sensitivity analysis (dashed lines are bootstrap point-wise 95% CIs); see Supplementary Text 3 for details of the sensitivity analysis. LOD, limit of detection.










Figure S29. Vaccine efficacy with sensitivity analysis by Day 29 (A) Anti-Spike IgG level, (B) Anti-RBD IgG level, (C) cID50 level, or (D) cID80 level. Vaccine efficacy estimates were obtained using the method of Gilbert, Fong, and Carone.¹² The upper boundary of the green shaded area is the estimate of the reverse cumulative distribution function of the marker in baseline SARS-CoV-2 negative per-protocol vaccine recipients. The pink solid line is point estimates assuming no unmeasured confounding; the dashed lines are bootstrap point-wise 95% CIs. The red solid line is point estimates assuming unmeasured confounding in a sensitivity analysis (dashed lines are bootstrap point-wise 95% CIs); see Supplementary Text 3 for details of the sensitivity analysis. LOD, limit of detection.








Table S9. Table of mediation effect estimates for quantitative markers with 95% confidence intervals.

Direct VE = VE comparing vaccine vs. placebo with marker set to distribution in placebo. Indirect VE = VE in vaccinated comparing observed marker vs. hypothetical marker under placebo. Prop. mediated = fraction of total risk reduction from vaccine attributed to antibody response.

Time	Assay	Direct VE	Indirect VE	Prop. mediated
Day 29	PsV Neutralization 50% Titer (Calibrated, cID50)	0.560 (0.422, 0.665)	0.832 (0.769, 0.878)	0.685 (0.585, 0.784)
Day 29	PsV Neutralization 80% Titer (Calibrated, cID80)	0.739 (0.601, 0.829)	0.717 (0.597, 0.801)	0.485 (0.345, 0.624)

References

1. Shen X, Tang H, McDanal C, et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe 2021;29:529-39 e3.

2. Kristiansen PA, Page M, Bernasconi V, et al. WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Lancet 2021;397:1347-8.

3. National Institute for Biological Standards and Control (NIBSC). Instructions for use of First WHO International Standard for anti-SARS-CoV-2 Immunoglobulin (Version 3.0, Dated 17/12/2020) NIBSC code: 20/136 <u>https://www.nibsc.org/science_and_research/idd/cfar/covid-19_reagents.aspx</u> Access date Jul 29, 2021.

4. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. **[Preprint]** Access date 25 Jun, 2021

https://doi.org/10.1101/2021.06.21.21258528 medRxiv 2021:2021.06.21.21258528. 5. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021;384:403-16.

6. Williamson BD, Gilbert PB, Simon NR, Carone M. A unified approach for inference on algorithm-agnostic variable importance. **[Preprint]** arXiv:2004.03683 [stat.ME] Access date 25 Jun, 2021. arXiv 2020.

7. Hubbard AE, Kherad-Pajouh S, van der Laan MJ. Statistical Inference for Data Adaptive Target Parameters. Int J Biostat 2016;12:3-19.

8. Neidich SD, Fong Y, Li SS, et al. Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. J Clin Invest 2019;129:4838-49.

9. Magaret CA, Benkeser DC, Williamson BD, et al. Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features. PLoS Comput Biol 2019;15:e1006952.

10. Williamson BD, Feng J, Simon N, Carone M. vimp: Perform Inference on Algorithm-Agnostic Variable Importance. Version 2.2.2. Published 2021-06-14. Available at <u>https://cran.r-project.org/web/packages/vimp/index.html</u> Access date 3 Jul, 2021.

11. Siber GR, Chang I, Baker S, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 2007;25:3816-26.

12. Gilbert PB, Fong Y, Carone M. Assessment of Immune Correlates of Protection via Controlled Risk and Controlled Vaccine Efficacy [**Preprint**] Access date 13 Jul, 2021. arXiv:2107.05734 [stat.ME]. 2021.

13. VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: Introducing the E-Value. Ann Intern Med 2017;167:268-74.

14. Ding P, VanderWeele TJ. Sensitivity Analysis Without Assumptions. Epidemiology 2016;27:368-77.